FUSION PROTEINS FOR THE TREATMENT OF METABOLIC DISORDERS

专利摘要:
fusion proteins for the treatment of metabolic disorders. the invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (fgf21) with improved pharmaceutical properties. in addition, methods for treating disorders associated with fgf21, including metabolic conditions, are described.
公开号:BR112014007069B1
申请号:R112014007069-5
申请日:2012-09-26
公开日:2020-12-15
发明作者:Brian R. Boettcher；Shari L. Caplan；Douglas S. Daniels；Norio Hamamatsu；Stuart Licht；Stephen Craig Weldon
申请人:Novartis Ag；
IPC主号:

专利说明:

Field of invention
[0001] The present invention relates to new fusion proteins that comprise fibroblast growth factor 21 (FGF21), known to improve the metabolic profiles in patients to whom they are administered. Background of the invention
[0002] The fibroblast growth factor (FGF) family is characterized by 22 genetically distinct homologous ligands that are grouped into seven subfamilies. FGF-21 is more closely related and forms a subfamily with FGF-19 and FGF-23. This FGF subfamily regulates several physiological processes that are uncommon to classic FGFs, namely, energy and bile acid homeostasis, glucose and lipid metabolism and phosphate homeostasis, as well as vitamin D. Furthermore, unlike other FGFs , this subfamily acts in an endocrine manner (Moore, DD (2007) Science 316, 1436-8; Beenken et al. (2009) Nature Reviews Drug Discovery 8, 235).
[0003] FGF21 is a 209 amino acid polypeptide containing a leader sequence formed by 28 amino acids (SEQ ID NO: 5). Human FGF21 has approximately 79% amino acid identity to mouse FGF21 and approximately 80% amino acid identity to mouse FGF21. Fibroblast growth factor 21 (FGF21) has been described as a treatment for ischemic vascular disease, wound healing and diseases associated with loss of lung function, bronchi or alveolar cells (Nishimura et al. (2000) Biochimica et Biophysica Acta , 1492: 203-206; Patent Publication WO01 / 36640; and Patent Publication WO01 / 18172). Although FGF-21 activates FGF receptors and downstream signaling molecules (downstream), including FRS2a and ERK, the direct interaction of FGFRs and FGF-21 was not detected. Studies have identified β-klotho, with high expression in the liver, in adipocytes and in the pancreas, as a determinant of the cellular response to FGF-21 and as a cofactor in the mediation of FGF-21 signaling through FGFRs (Kurosu, H et al. (2007) J Biol Chem 282, 2668795). FGF21 is a potent agonist of the FGFR1 (IlIc), FGFR2 (lllc) and FGFR3 (lllc) -β-klotho signaling complexes.
[0004] FGF-21 has been shown to induce insulin-independent glucose uptake. In addition, it has also been shown to mitigate hyperglycemia in a variety of diabetic rodent models. In addition, transgenic mice with FGF-21 overexpression have shown that they are resistant to metabolic abnormalities induced by diet, in addition to demonstrating reduced body weight and fat mass and improved insulin sensitivity (Badman, MK et al. (2007) Cell Metab 5, 426-37). The administration of FGF-21 to non-human diabetic primates caused a decline in fasting plasma glucose, triglyceride, insulin and glucagon levels and led to an improvement in lipoprotein profiles, including an increase of almost 80% in cholesterol -HDL (Kharitonenkov, A. et al. (2007) Endocrinology 148, 774- 81). Recent studies investigating the mechanisms of action at the molecular level of FGF21 have identified FGF21 as an important endocrine hormone that helps control adaptation to the fasting state (Badman et al. (2009) Endocrinology 150, 4931; lnagaki et al. (2007 ) Cell Metabolism 5, 415). This provides a previously unseen downstream link to PPARa, whereby the liver communicates with the rest of the body to regulate the biology of energy homeostasis (Galman et al. (2008) Cell Metabolism 8, 169; Lundasen et al. (2007) Biochemical and Biophysical Rese-arch Communications 360, 437).
[0005] FGF21 regulates adipocyte homeostasis by activating an AMPK / SIRT1 / PGC1α pathway that inhibits PPARy expression and increases mitochondrial function (Chau et al. (2010) PNAS 107, 12553). FGF21 also increases the uptake of glucose by skeletal muscle, as measured in cultured human myotubes and isolated mouse tissue. Treatment with FGF21 of islet cells leads to improved function and survival by activating the ERK1 / 2 and Akt pathways (Wente et al. (2006) Diabetes 55, 2470). Treatment with FGF21 also results in gene expression altered for lipogenesis and for enzymes responsible for the oxidation of fatty acids in rodent livers, probably through HNF4α and Foxa2 signaling.
[0006] A difficulty associated with using FGF-21 directly as a biotherapeutic agent is that its half-life is very short (Kharitonenkov, A. et al. (2005) Journal of Clinical Investigation 115: 16271635) In mice, the half-life of human FGF21 is 0.5 to 1 hour and, in Cynomolgus monkeys, the half-life is 2 to 3 hours. FGF21 can be used in a sterile multipurpose pharmaceutical formulation. However, an adverse effect of preservatives, that is, m-cresol on its stability was determined under these conditions.
[0007] In the development of a FGF21 protein for use as a therapeutic agent in the treatment of type 1 and type 2 diabetes mellitus and other metabolic conditions, an increase in half-life and stability would be desirable. FGF21 proteins with enhanced half-life and stability would allow less frequent administration to patients to whom the protein is administered. Of course, there is a need for a stable aqueous protein formulation to be developed for the therapeutic protein FGF21.
[0008] Furthermore, a considerable challenge in the development of FGF21, as a pharmaceutical protein, is to deal with its physical and chemical instabilities. The variety of the composition and the characteristics of proteins define specific behaviors such as folding, conformational stability and unfolding / denaturation. Such characteristics must be addressed when aiming to stabilize proteins throughout the development of conditions for pharmaceutical formulations that use aqueous protein solutions (Wang, W., Int. J. of Pharmaceutics, 18, (1999)). A desired effect in stabilizing therapeutic proteins of interest, for example, the proteins of the present invention, is to increase resistance to proteolysis and enzymatic degradation and thereby improve protein stability and reduce protein aggregation. Summary of the invention
[0009] The invention relates to the identification of new fusion proteins which comprise fibroblast growth factor 21 (FGF21) and which have improved pharmaceutical properties above wild-type FGF21 and its variants under pharmaceutical formulation conditions, for example , are more stable, have the ability to improve metabolic parameters of individuals to whom they are administered, are less susceptible to proteolysis and enzymatic degradation and are less likely to aggregate and form complexes. The fusion proteins of the invention comprise truncations, mutations and variants of FGF21.
[00010] Additionally, methods for treating disorders associated with FGF21 are described, as well as other metabolic, endocrine and cardiovascular disorders, such as obesity, type 1 and type 2 diabetes mellitus, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, disease renal, diabetic complications, neuropathy, gastroparesis, disorders associated with severe inactivating mutations in the in-suline receptor and other metabolic disorders, and to reduce the mortality and morbidity of critically ill patients.
[00011] The fusion proteins of the present invention can be used in an injectable form once a week alone or combined with oral antidiabetic agents that will improve glycemic control, body weight and lipid profile of patients with type 1 and type 2 diabetes mellitus Proteins can also be used to treat obesity or other conditions associated with FGF21.
[00012] The fusion proteins of the invention overcome the significant obstacles of physical instabilities associated with therapeutic proteins, including, for example, with the administration of wild-type FGF21, by presenting proteins that are more stable, less susceptible to proteolysis and degradation enzymatic and less likely to aggregate and form complexes than wild-type FGF21 under pharmaceutical formulation conditions.
[00013] In a first aspect, the invention provides Fibroblast Growth Factor 21 (FGF21) fusion proteins that comprise one or more of the sequences listed in Table 1 and described in more detail below. The FGF21 sequences listed in Table 1 can be variants of the wild type FGF21 sequence, for example, the wild type FGF21 sequence with NCBI reference number NP_061986.1, and found in issued patents such as, for example, US 6 716 626B1, granted to Chiron Corporation.
[00014] Said fusions can be, for example, between the FGF21 variant sequences, for example, the sequences in Table 1, and other molecules (a non-FGF21 part), for example, an IgG constant domain or its fragment (for example, the Fc region), human albuminaser (HSA) or polypeptides that bind to albumin. In a preferred embodiment, the non-FGF21 part of the molecule is an Fc region.
[00015] Other embodiments are taken to polynucleotides that encode the fusion proteins of the invention, to a vector that contains said polynucleotides and to a host cell that carries said vector.
[00016] Additionally, the present invention provides methods used to generate the fusion proteins of the invention, wherein such methods involve the modification of the wild-type FGF21 protein, by means of, for example, site-specific incorporation of amino acids in positions of interest within the wild-type FGF21 protein, as well as the fusion between the FGF21 part of the molecule and other molecules, for example, an IgG constant domain or its fragment (for example, the Fc region), human serum albumin (HSA) or polypeptides that bind to albumin. Said modifications and fusions reinforce the biological properties of the fusion proteins of the invention in relation to the wild-type protein versions, as well as, in some cases, serve as connection points for, for example, markings and agents that extend the half-life. of proteins and for the purpose of fixing said variants to the surface of a solid support. Related embodiments of the invention are methods of producing cells capable of producing said proteins of the invention and of producing vectors containing the DNA encoding said variants and fusions.
[00017] In various embodiments, the fusion proteins of the invention described herein may comprise one or more fragments of FGF21 wild-type sequences, including fragments so small that they contain only 8-12 amino acid residues in length, and in which the polypeptide is able to decrease blood glucose in a mammal. In various embodiments, the fusion proteins of the invention described herein can comprise one or more variants of the FGF21 wild-type sequences, for example, with one or more deletions, insertions, additions or substitutions in relation to their wild-type sequences.
[00018] In some embodiments, the fusion proteins of the invention described herein can be covalently linked to one or more polymers, such as polyethylene glycol (PEG) or polyisalic acid, either in the position of site-specific amino acid changes made in relation to FGF21 of the wild type, or in the position of amino acids commonly shared with the wild type versions of these proteins. The PEG group is linked in such a way as to enhance and / or not interfere with the biological function of the constituent parts of the fusion proteins of the invention, for example, the FGF21 protein variants. In other embodiments, the polypeptides of the invention may be fused to a heterologous amino acid sequence, optionally via a linker, such as GS, GGGGSGGGGSGGGGS (SEQ ID NO: 6). The heterologous amino acid sequence can be a constant domain of IgG or its fragment (for example, the Fc region), human serum albumin (HSA) or polypeptides that bind to albumin. Such fusion proteins described herein can also form multimers.
[00019] In some embodiments, a heterologous amino acid sequence (e.g., HSA, Fc, etc.) is fused to the terminal amino of the fusion proteins of the invention. In other embodiments, the heterologous fusion amino acid sequence (e.g., HSA, Fc, etc.) is fused to the terminal carboxyl of the fusion proteins of the invention.
[00020] Yet another embodiment leads to methods for treating a patient who exhibits one or more disorders associated with FGF21, such as obesity, type 2 diabetes mellitus, type 1 diabetes mellitus, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), steatohepatitis non-alcoholic (NASH), insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, kidney disease, diabetic complications, neuropathy, gastroparesis, disorders associated with inactivating mutations in the insulin receptor and other metabolic disorders, which comprise administering to said patient in need of such treatment a therapeutically effective amount of one or more proteins of the invention or one of its pharmaceutical compositions.
[00021] The invention also provides pharmaceutical compositions comprising the fusion proteins of the invention described herein and a pharmaceutically acceptable formulation agent. Such pharmaceutical compositions can be used in a method to treat a metabolic disorder, and the method comprises administering to a human patient in need of such treatment a pharmaceutical composition of the invention. Non-limiting examples of metabolic disorders that can be treated include type 1 and type 2 diabetes mellitus and obesity.
[00022] These and other aspects of the invention will be elucidated in the following detailed description of the invention. Brief description of the drawings
[00023] Figures 1A-1D show that V188 has improved efficacy in the diabetic ob / ob mouse model above V76. V188 shows superior results when administered at 1 milligram per kilogram (mpk), when compared to the 5 milligrams per kilogram to which V76 was administered. Figure 1A shows readings of the plasma glucose level in the fed state (circles represent vehicle (PBS - saline with phosphate buffer), squares represent V76 at 5 mpk and triangles represent V188 at 1 mpk). Figure 1B shows readings of the plasma insulin level in the fed state (from left to right: vehicle, V76 at 5 mpk and V188 at 1 mpk). Figure 1C shows body weight readings (from left to right: vehicle, V76 at 5 mpk and V188 at 1 mpk). Figure 1D shows readings of the lipid content in the liver (from left to right: vehicle, V76 at 5 mpk and V188 at 1 mpk).
[00024] Figures 2A-2D show that V101 has improved efficacy in the diabetic ob / ob mouse model above V76. V101 shows superior results when administered at 1 milligram per kilogram (mpk), when compared to the 5 milligrams per kilogram to which V76 was administered. Figure 2A shows readings of the plasma glucose level in the fed state (circles represent vehicle (PBS - saline with phosphate buffer), squares represent V76 at 5 mpk and triangles represent V101 at 1 mpk). Figure 2B shows readings of the plasma insulin level in the fed state (from left to right: vehicle, V76 at 5 mpk and V101 at 1 mpk). Figure 2C shows body weight readings (from left to right: vehicle, V76 at 5 mpk and V101 at 1 mpk). Figure 2D shows readings of the lipid content in the liver (from left to right: vehicle, V76 at 5 mpk and V101 at 1 mpk).
[00025] Figures 3A-3D show that V103 has improved efficacy in the diabetic ob / ob mouse model above V76. V103 shows superior results when administered at 1 milligram per kilogram (mpk), when compared to the 5 milligrams per kilogram to which V76 was administered. Figure 3A shows readings of the plasma glucose level in the fed state (circles represent vehicle (PBS - saline with phosphate buffer), squares represent V76 at 5 mpk and triangles represent V103 at 1 mpk). Figure 3B shows readings of the plasma insulin level in the fed state (from left to right: vehicle, V76 at 5 mpk and V103 at 1 mpk). Figure 3C shows body weight readings (from left to right: vehicle, V76 at 5 mpk and V103 at 1 mpk). Figure 3D shows readings of the lipid content in the liver (from left to right: vehicle, V76 at 5 mpk and V103 at 1 mpk).
[00026] Figures 4A-4D demonstrate the superior pharmacokinetic and thermodynamic properties possessed by the fusion proteins of the invention over the FGF21 fusion proteins existing in the art. Figure 4A shows the plasma concentrations of fusion proteins of the invention in PCT Publication WO10 / 129600, described as Fc-L (15) -FGF21 (L98R, P171G) and Fc-L (15) -FGF21 (L98R, P171G, A180E ), after IV injection of the said fusion in mice. Figure 4B shows the pharmacokinetic properties of the fusion proteins of the invention (V101, V103 and V188) after a single IV dose in the mouse, as analyzed by an anti-Fc ELISA assay, compared to the pharmacokinetic data generated in the mouse by V76 in a previous study with ELISA assay using an anti-FGF21 antibody. Figure 4C shows an on-site verification of the fusion proteins of the invention by the Western Blotting technique with an anti-FGF21 antibody, which is compatible with data by antiFc ELISA in 120 hours and 15 days. The samples in the Blottings are as follows: A represents V101, B represents V103 and C represents V188. The control is V101 and serum. Figure 4D demonstrates the significantly increased thermodynamic stability of the fusion proteins of the invention when compared to V76. From top to bottom, the figure represents V101, V103 and V188, all of which have improved melting temperatures (Tm) when compared to V76 (Tm <50 ° C (not shown)) and wild-type FGF21 (Tm = 46, 5 ° C ± 0.3 (not shown)). Detailed description of the invention
[00027] The fusion proteins of the present invention represent modified versions of the full length of the wild-type FGF21 polypeptide, as known in the art. The FGF21 wild type sequence will serve as a reference sequence (SEQ ID NO: 1), for example, when comparisons between the FGF21 wild type sequence and protein variants are necessary. The FGF21 wild-type sequence has the NCBI reference sequence number NP_061986.1e can be found in issued patents, such as, for example, US 6 716 626B1, issued to Chiron Corporation (SEQ ID NO: 1). Met Asp Ser Asp Glu Thr Gly Phe Glu His Ser Gly Leu Trp Vai Ser 15 10 15 Vai Leu Ala Gly Leu Leu Leu Gly Ala Cys Gin Ala His Pro lie Pro 20 25 30 Asp Ser Ser Pro Leu Leu Gin Phe Gly Gly Gin Vai Arg Gin Arg Tyr 35 40 45 Leu Tyr Thr Asp Asp Ala Gin Gin Thr Glu Ala His Leu Glu He Arg 50 55 60 Glu Asp Gly Thr Vai Gly Gly Ala Wing Asp Gin Ser Pro Glu Ser Leu 65 70 75 80 Leu Gin Leu Lys Ala Leu Lys Pro Gly Vai lie Gin He Leu Gly Vai 85 90 95 Lys Thr Ser Arg Phe Leu Cys Gin Arg Pro Asp Gly Ala Leu Tyr Gly 100 105 HO Ser Leu His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Leu Leu Leu 115 120 125 Glu Asp Gly Tyr Asn Vai Tyr Gin Ser Glu Ala His Gly Leu Pro Leu 130 135 140 His Leu Pro Gly Asn Lys Ser Pro His Arg Asp Pro Ala Pro Arg Gly 145 150 155 160 Pro Ala Arg Phe Leu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 165 170 175 Pro Pro Gly He Leu Ala Pro Gin Pro Pro Asp Vai Gly Ser Ser Asp 180 185 190 Pro Leu Ser Met Vai Gly Pro Ser Gin Gly Arg Ser Pro Ser Tyr Ala 195 200 205 Ser 209
[00028] The coding sequence corresponding to the complete mRNA FGF21 polypeptide (NCBI NM_019113.2 number of reference sequence) is shown below (SEQ ID NO: 2): 1 ctgtcagctg aggatccagc cgaaagagga gccaggcact caggccacct gagtctactc 61 acctggacaa ctggaatctg gcaccaattc taaaccactc agcttctccg agctcacacc 121 ccggagatca cctgaggacc cgagccattg atggactcgg acgagaccgg gttcgagcac 181 tcaggactgt gggtttctgt gctggctggt cttctgctgg gagcctgcca ggcacacccc 241 atccctgact ccagtcctct cctgcaattc gggggccaag tccggcagcg gtacctctac 301 acagatgatg cccagcagac agaagcccac ctggagatca gggaggatgg gacggtgggg 361 ggcgctgctg accagagccc cgaaagtctc ctgcagctga aagccttgaa gccgggagtt 421 attcaaatct tgggagtcaa gacatccagg ttcctgtgcc agcggccaga tggggccctg 481 tatggatcgc tccactttga ccctgaggcc tgcagcttcc gggagctgct tcttgaggac 541 ggatacaatg tttaccagtc cgaagcccac ggcctcccgc tgcacctgcc agggaacaag 601 tccccacacc gggaccctgc accccgagga ccagctcgct tcctgccact accaggcctg 661 cccccggagac accccgggt acccgccgg 721 g tgtgggctcc tcggaccctc tgagcatggt gggaccttcc cagggccgaa gccccagcta cgcttcctga 781 agccagaggc tgtttactat gacatctcct ctttatttat taggttattt atcttattta 841 tttttttatt tttcttactt gagataataa agagttccag aggagaaaaa 901 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
[00029] The mature FGF21 sequence lacks a leader sequence and may also include other modifications of a polypeptide, such as proteolytic processing of the amino termination (with or without a leader sequence) and / or the carboxyl termination, cleavage of a minor polypeptide from a major precursor, N-linked and / or O-linked glycosylation and other post-translational modifications understood by those skilled in the art. A representative example of a mature FGF21 sequence has the following sequence (SEQ 25 ID NO: 3, which represents the amino acid positions 29-209 of the complete FGF21 protein sequence (NCBI reference sequence number NP_061986.1)): His Pro 11 $ Pro Asp Ser Ser Pro Lea Leu Gin Phe Gly Gly Gin Vai 5 10 15 Arg Gin Arg Tyr Leu Tyr Thr Asp Asp Ala Gin Gin Tbr Glu Ala His 20 25 30 Leu Glu 11 $ Arg Glu Asp Gly Thr Vai Gly Gly Wing Wing Asp Gin Ser 35 '40 45 Pro Glu Ser Leu Leu Gin Leu Lys Wing Leu Lys Pro Gly Vai He Gin 50 55 '' 60 He Leu Gly Vai Lys Thr Ser Arg Phe Leu Cys Gin Arg Pre Asp Gly 65 7 (1 75 30 Alu Leu Tyr Gly Ser Leu His Phe Asp Pro Glu Ala Cys Ser Phe Arg 85 90 95 Glu Leu Leu Leu Glu Asp Gly Tyr Asπ Vai Tyr Gin Ser Glu Ala His IOC 105 110 Gly Leu Pro Leu His Leu Pro Gly Asn Lys Ser Pro His Arg Asp Pro 115 120 "125 Wing Pro Arg Gly Pre Wing Arg Phu Leu Pro Leu Pro Gly Leu Pro Pro 130 '135 140 Wing Leu Pre Glu Pro Fro Gly He Leu Wing Pro Gin Pro Pro Asp Vai 145 150 155 1 60 Gly Ger Ser Asp Pro Leu Ser Met Vai Gly Pro Ser Gin Gly Arg Ser 165 170 175 Pro Ser Tyr Ala Ser ISC
[00030] The corresponding coding sequence of the cDNA for the FGF21 mature polypeptide (SEQ ID NO: 3) is shown below (SEQ ID NO: 4): 1 caccccatcc ctgactccag tcctctcctg caattcgggg gccaagtccg gcagcggtac 61 ctctacacag atgatgccca gcagacagaa gcccacctgg agatcaggga ggatgggacg 121 gtggggggcg ctgctgacca gagccccgaa agtctcctgc agetgaaage ettgaageeg 181 ggagttattc aaatcttggg agtcaagaca tccaggttcc tgtgccagcg gccagatggg 240 gccctgtatg gatcgctcca ctttgaccct gaggeetgea gcttccggga getgettett 301 gaggaeggat acaatgttta ccagtccgaa gcccacggcc tcccgctgca cctgccaggg 360 aacaagtccc cacaccggga ccctgcaccc cgaggaccag ctcgcttcct gccactacca 421 ggcctgcccc ccgcactccc ggagccaccc ggaatcctgg ccccccagcc ccccgatgtg 481 ggctcctcgg accctctgag catggtggga ccttcccagg gccgaagccc cagctacgct 541 teetga
[00031] The fusion proteins of the invention may comprise protein variants or mutants of the wild-type proteins listed in this specification, for example, FGF21 variants. In this specification, the terms "protein variant", "human variant", "polypeptide or protein variant", "variant", "mutant", as well as any similar terms or their specific versions (for example, "FGF21 protein variant" , "variant", "FGF21 mutant", etc.) define protein or polypeptide sequences that comprise modifications, truncations, other variants of natural (i.e., wild type) protein or polypeptide homologs or corresponding native sequences. "Variant FGF21" or "mutant FGF21", for example, is described in relation to the wild type (i.e., natural) FGF21 protein as described herein.
[00032] Representative sequences of the fusion proteins of the invention are listed in Table 1. Descriptions of said fusions include the variant of FGF21 and, where applicable, a linker. The changes or substitutions employed by the FGF21 variant are numbered and described in relation to the wild type FGF21. As an example, "Variant 101 (V101)" (SEQ ID NO: 10) is a fusion of Fc-FGF21 with a two amino acid linker and the following substitutions made for FGF21 wild type FGF21: Q55C, A109T, G148C, K150R, P158S, P174L, S195A, P199G, G202A. Table 1: Variant proteins from Fc to FGF21 fusion


* - Note that the wild type FGF21 sequence in this table refers to the reference sequence NCBI number NP_061986.1 (SEQ ID NO: 1) unless otherwise specified. All mutations in the FGF21 group and the corresponding amino acid numbering of the referred mutations refer to (SEQ ID NO: 1) not to the complete sequences in this table, which may also include Fc and ligand regions.
[00033] The variants or mutants used in the fusion proteins of the invention, for example, wild-type FGF21 variants, have at least one substituted, added and / or removed amino acid in relation to the wild-type protein, the variants may include truncations at N and / or C-terminal in relation to wild type proteins. In general terms, a variant has some modified property, structural or functional, of the wild type protein. For example, the variant may have enhanced or improved physical stability in concentrated solutions (for example, less aggregation by hydrophobic mediation), enhanced or improved plasma stability when incubated with blood plasma or enhanced or improved bioactivity while maintaining a favorable bioactivity profile .
[00034] Acceptable amino acid substitutions and modifications that make up differences between the portions of the fusion proteins of the invention and their wild-type comparator proteins include, but are not limited to, one or more amino acid substitutions, including substitutions by unnatural amino acid analogs, and truncations. Accordingly, the fusion proteins of the invention (for example, the fusion proteins of the invention) include, but are not limited to, site-directed mutants, truncated polypeptides, mutants resistant to proteolysis, mutants that reduce aggregation, mutants of combinations and proteins of merger, as described herein.
[00035] The person skilled in the field of protein expression will recognize that the sequence of methionine or methionine-arginine can be introduced at the N-terminus of any of the fusion proteins of the invention, for expression in E. coli, and these are contemplated within the context of this invention.
[00036] The fusion proteins of the invention may have increased compatibility with pharmaceutical preservatives (for example, m-cresol, phenol, benzyl alcohol), whereby making it possible to prepare a pharmaceutical formulation with preservatives that maintains the physicochemical properties and the biological activity of the protein during storage. Thus, variants with enhanced pharmaceutical stability, in relation to the wild type, present improved physical stability in solutions concentrated both in physiological conditions and in those of pharmaceutical formulation with preservative, while maintaining biological potency. As a non-limiting example, the fusion proteins of the invention may be more resistant to proteolysis and enzymatic degradation; may have improved stability; and may be less likely to aggregate than their wild-type counterparts or corresponding native sequences. In this specification, these terms are not mutually exclusive or limiting, as it is entirely possible that a given variant has one or more modified properties of the wild type protein.
[00037] The invention also encompasses nucleic acid molecules that encode the fusion proteins of the invention and which comprise, for example, an amino acid sequence of FGF21 that is at least approximately 95% identical to the amino acid sequence of SEQ ID NO: 3, but in which specific residues that give a desirable property to the FGF21 protein variant, for example, improved potency against FGF21 receptors, resistance to proteolysis, increased half-life or aggregation-reducing properties and their combinations, do not have been further modified. In other words, with the exception of residues in the FGF21 mutant sequence that have been modified to provide resistance to proteolysis, reduced aggregation or other properties, approximately 5% may have been modified (alternately 4%, alternately 3%, alternately 2%, alternately 1%) of all other amino acid residues in the FGF21 mutant sequence. Such FGF21 mutants have at least one activity of the wild-type FGF21 polypeptide.
[00038] The invention also encompasses a nucleic acid molecule comprising a nucleotide sequence that is at least approximately 85% identical, and more preferably, at least approximately 90 to 95% identical to the nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 4, but where the nucleotides encoding amino acid residues that confer proteolysis resistance, reduced aggregation or other properties to the encoded proteins have not been further modified. In other words, with the exception of nucleotides that encode residues in the mutant FGF21 sequences that have been modified to provide resistance to proteolysis, reduced aggregation or other properties, approximately 15% may have been modified, and more preferably close 10 to 5% of all other nucleotides in the mutant sequence. Such nucleic acid molecules encode proteins that have at least one activity of their wild-type counterparts.
[00039] The present invention provides methods used to generate the fusion proteins of the invention, wherein such methods involve site-specific and non-site-specific modification of the wild-type versions of the proteins (e.g., the wild-type FGF21 protein as described herein), for example, truncations of wild-type proteins and the site-specific incorporation of amino acids in positions of interest within wild-type proteins. Said modifications reinforce the biological properties of the fusion proteins of the invention in relation to wild type proteins, as well as, in some cases, serve as points of attachment for, for example, labels and agents for extending the half-life of proteins, and for the purpose of fixing said variants to the surface of a solid support. Related embodiments of the invention are methods of producing cells capable of producing said fusion proteins of the invention and of producing vectors containing DNA encoding said variants.
[00040] In certain embodiments, such modifications, for example, site-specific modifications, are used to attach conjugates, for example, PEG groups to proteins, polypeptides and / or peptides of the invention, for the purpose, for example, of extending the half-life or otherwise improve the biological properties of said proteins, polypeptides and / or peptides. These techniques are described in more detail below.
[00041] In other embodiments, such modifications, for example, site-specific modifications are used to attach other polymers, small molecules and recombinant protein sequences that extend the half-life of the protein of the invention. One such embodiment includes the attachment of fatty acids or specific compounds that bind albumin to proteins, polypeptides and / or peptides. In other embodiments, the modifications are made to a particular type of amino acid and can be attached to one or more sites on the protein.
[00042] In other embodiments, such modifications, for example, site-specific modifications, are used as a means of binding for the production of wild type multimers and / or variants, for example, dimers (homodimers or heterodimers), trimers or teems drivers. Such multimeric protein molecules may additionally contain groups such as PEG, sugars and / or attached PEG-cholesterol conjugates or be fused at the amino or carboxyl terminus to other proteins such as Fc, human serum albumin (HSA), etc.
[00043] In other embodiments, such site-specific modifications are used to produce proteins, polypeptides and / or peptides, in which the position of pyrrolysin or its analog or unnatural amino acids (para-acetyl-Phe, para-azido- Phe), incorporated in a site-specific way, allows controlling the orientation and fixing such proteins, polypeptides and / or peptides to the surface of a solid support or so that they have groups such as PEG, sugars and / or PEG-cholesterol conjugates attached.
[00044] In other embodiments, such site-specific modifications are used to promote cross-linking of proteins, polypeptides and / or peptides in a site-specific manner, whereby forming oligomers including, among others, heterodimers and heterotrimers. In other embodiments, such site-specific modifications are used to promote cross-linking of proteins, polypeptides and / or peptides in a site-specific manner, whereby forming protein-protein conjugates, protein-polypeptide conjugates, protein-protein conjugates peptide, polypeptide-polypeptide conjugates, polypeptide-peptide conjugates or peptide-peptide conjugates. In other embodiments, a site-specific modification can include a branching point to allow more than one type of molecule to be attached to a single site on a protein, polypeptide or peptide.
[00045] In other embodiments, the modifications listed here can be made non-site-specific and result in protein-protein conjugates, protein-polypeptide conjugates, protein-peptide conjugates, polypeptide-polypeptide conjugates, polypeptide-peptide conjugates or peptide-peptide conjugates of the invention. Definitions
[00046] Several definitions are used throughout this document. Most words have the meaning that would be attributed to those words by the technician in the subject. Specifically defined words, either below or elsewhere in this document, have the meaning provided in the context of the present invention as a whole and as are typically understood by those skilled in the art.
[00047] In this specification, the term "FGF21" refers to a member of the fibroblast growth factor (FGF) protein family. An FGF21 amino acid sequence (GenBank accession number NP_061986.1) is presented as SEQ ID NO: 1, the corresponding polynucleotide sequence of which is presented as SEQ ID NO: 2 (NCBI reference sequence number NM_019113.2). "FGF21 vari-ante", "FGF21 mutant" and similar terms describe the modified version of the FGF21 protein, for example, with deleted, added, modified or substituted residues of the constituent amino acids.
[00048] In this specification, the term "FGF21 receptor" refers to a receptor for FGF21 (Kharitonenkov, A, et al. (2008) Journal of Cellular Physiology 215: 1-7; Kurosu, H. et al. (2007) JBC 282: 26687-26695; Ogawa, Y. et al. (2007) PNAS 104: 7432-7437).
[00049] The term "FGF21 polypeptide" refers to a naturally occurring polypeptide that is expressed in humans. For descriptive purposes, the term "FGF21 polypeptide" may be used interchangeably to refer to any complete FGF21 polypeptide, for example, SEQ ID NO: 1, which consists of 209 amino acid residues and which is encoded by the nucleotide sequence SEQ ID NO: 2; any mature form of the polypeptide, consisting of 181 amino acid residues and in which the 28 amino acid residues at the amino terminus of the complete FGF21 polypeptide (ie, which constitutes the signaling peptide) have been removed.
[00050] "Variant 76," in this specification, is a protein variant of FGF21, featuring a branched 40 kDa PEG linked via Cys154 and eight mutations punctuated with respect to the 177-amino acid wild-type protein. The synthesis of the variant is described in more detail in this report, and the protein sequence is shown in Table 1 and SEQ ID NO: 9.
[00051] The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of the present invention that (1) has been separated from at least approximately 50 percent of proteins, lipids, carbohydrates or other materials with which it is naturally found when the total nucleic acid is isolated from the cells of origin, (2) it is not linked to all or part of a polypeptide to which the "isolated nucleic acid molecule" is linked in nature; (3) it is operationally linked to a polynucleotide to which it is not linked in nature or (4) it does not occur in nature as part of a larger polypeptide sequence. Preferably, the isolated nucleic acid molecule of the present invention is substantially free of any other nucleic acid contaminating molecules or other contaminants that are found in its natural environment that would interfere with its use in the production of the polypeptide or its therapeutic, diagnostic, prophylactic or in research.
[00052] The term "vector" is used to refer to any molecule (for example, nucleic acid, plasmid or virus) used to transfer coding information to a host cell.
[00053] The term "expression vector" refers to a vector suitable for transforming a host cell and containing nucleic acid sequences that direct and / or control the expression of inserted heterologous nucleic acid sequences. Expression includes, among others, processes such as transcription, translation and splicing (fragment removal) of RNA, if introns are present.
[00054] The term "operationally linked", in this specification, refers to an arrangement of flanking strings, in which the flanking sequences so described are configured or are set up to perform their usual function. Elements of fusion proteins can be operationally linked to one another as they would be with a natural endogenous protein and / or to combine elements different from said fusion proteins in a synergistic manner.
[00055] At the nucleotide level, a flanking sequence operably linked to a coding sequence may have the ability to effect replication, transcription and / or translation of the coding sequence. For example, a coding sequence is operably linked to a promoter when the promoter is able to direct the transcription of that coding sequence. A flanking sequence does not need to be contiguous to the coding sequence, as long as it works correctly. Therefore, for example, untranslated, yet transcribed intervening sequences can be present between a promoter sequence and the coding sequence, and yet the promoter sequence can be considered "operationally linked" to the coding sequence.
[00056] The term "host cell" is used to refer to a cell that has been transformed or that is capable of being transformed with a nucleic acid sequence and after expressing a selected gene of interest. The term includes the progeny of the precursor cell, whether the progeny is identical or not in morphology or in genetic makeup to the original precursor, provided that the selected gene is present.
[00057] The term "amino acid" in this specification refers to natural amino acids, unnatural amino acids, amino acid analogues and amino acid mimetides that act in a similar way to natural amino acids, all their D and L stereoisomers if its structure allows for such stereoisomeric forms. In this specification, amino acids are designated by their names, their commonly known symbols made up of 3 letters or by the symbols in one letter recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
[00058] The term "naturally occurring" when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells and the like, refers to materials that are found in nature and not manipulated by man. Likewise, "unnaturally occurring", in this specification, refers to a material that is not found in nature or that has been structurally modified or synthesized by man. When used in connection with nucleotides, the term "naturally occurring" refers to the bases adenine (A), cytosine (C), guanine (G), thymine (T) and uracil (U). When used in connection with amino acids, the term "naturally occurring" refers to the 20 conventional amino acids (ie, alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), serine (S), threonine (T), valine (V), tryptophan (W) and tyrosine (Y)), as well as selenocysteine, pyrrolysin (Pyl or O) and pyrroline-carboxy lysine (Pel or Z ).
[00059] Pyrrolysin (Pyl) is a naturally occurring amino acid found within methylamine methyltransferases from methanogenic arteries of the Methanosarcina family. Pyrrolysin is a lysine analogue incorporated by concomitant translation into UAG codons in frame in the respective mRNA and is considered the 22nd natural amino acid.
[00060] As described at least in PCT Patent Publication WO2010 / 48582 (Applicant IRM, LLC), attempts to biosynthesize pyrrolysin (Pyl) in E. coli resulted in the formation of "demethylated pyrrolysin", designated in this specification as pyrroline-carboxy-lysine or Pel. "Pel" in this specification refers to Pcl-A or Pcl-B.
[00061] The terms "unnatural amino acid" and "unnatural amino acid" in this specification are alternately intended to represent amino acid structures that cannot be generated by biosynthesis in any organism using unmodified or modified genes of any organism, whether they are the same or different. The terms refer to an amino acid residue that is not present in the naturally occurring (wild-type) protein sequence of FGF21 or in the sequences of the present invention. These include, but are not limited to, modified amino acids and / or analogues of amino acids other than one of the 20 naturally occurring amino acids, selenocysteine, pyrrolysin (Pyl) or pyrroline-carboxy-lysine (Pel, for example, as described in the Publication of the PCT patent WO2010 / 48582). Such unnatural amino acid residues can be introduced by substituting naturally occurring amino acids and / or by inserting unnatural amino acids in the naturally occurring (wild-type) protein sequence of FGF21 or in the sequences of the invention. The unnatural amino acid residue can also be incorporated in such a way that a desired functionality is transmitted to the FGF21 molecule, for example, the ability to link a functional group (for example, PEG). When used in connection with amino acids, the symbol "U" will mean "unnatural amino acid" in this specification.
[00062] Additionally, it is understood that such "unnatural amino acids" require a modified tRNA and a modified tRNA synthase (RS) for incorporation into a protein.
[00063] These “selected” orthogonal tRNA / RS pairs are generated by a selection process as developed by Schultz et al. or by random or targeted mutation. For example, pyrroline-carboxy-lysine is a "natural amino acid" generated in a biosynthetic way by genes transferred from an organism to host cells and incorporated into proteins using natural tRNA and tRNA synthase genes, while p- aminophenylalanine (See, Generation of a bacterium with a 21 amino acid genetic code, Mehl RA, Anderson JC, Santoro SW, Wang L, Martin AB, King DS, Horn DM, Schultz PG. J Am Chem Soc. 2003 Jan 29; 125 (4): 935-9) is an "unnatural amino acid" because, although generated by biosynthesis, it is incorporated into proteins by a "selected" orthogonal tRNA / tRNA pair.
[00064] Encoded modified amino acids include, but are not limited to, hydroxyproline, Y-carboxyglutamate, O-phosphoserine, azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4 -aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, tertiary butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminoproprionic acid, N-ethylglycine, N-methylglycine, N-ethyl-asparagine, homoproline, hydroxylysine, allohydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine, N-methylglycine , N-methyl-isoleucine, N-methylpentylglycine, N-methylvaline, naphthalanine, norvaline, norleucine, ornithine, pentylglycine, pipecolic acid and thioproline. The term "amino acid" also includes naturally occurring amino acids that are metabolites of certain organisms, but that are not encoded by the genetic code for incorporation into proteins. Such amino acids include, but are not limited to, ornithine, D-ornithine and D-arginine.
[00065] The term "amino acid analog" in this specification refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, for example only, an α-carbon that is linked to a hydrogen , a carboxyl group, an amino group and an R group. Amino acid analogs include the natural and unnatural amino acids that are chemically blocked, reversible or irreversibly, or that your carboxy group at the C-terminal, your amino group at the N- terminal and / or its functional groups in the side chain are chemically modified. Such analogs include, but are not limited to, methionine sulfoxide, methionine sulfone, S- (carboxymethyl) -cysteine, S- (carboxymethyl) -cysteine sulfoxide, S- (carboxymethyl) -cysteine sulfone, (beta-methyl ester) of aspartic acid, N - ethylglycine, alanine carboxamide, homoserine, norleucine and methionine methyl sulfonium.
[00066] The term "amino acid mimetic" in this specification refers to chemical compounds that have a different structure from the general chemical structure of an amino acid, but which works in a similar way to a naturally occurring amino acid.
[00067] The term "biologically active variant" refers to any polypeptide variant used in the fusion proteins of the invention, for example, as a constituent protein of fusions, which has an activity of its wild-type protein or polypeptide counterpart (for example , naturally occurring), such as the ability to modulate blood glucose, HbA1c, insulin, triglyceride or cholesterol levels; increase pancreatic function; reduce lipid levels in the liver; reduce body weight; and improving glucose tolerance, energy expenditure or insulin sensitivity, regardless of the type or number of changes that have been made to the polypeptide variant. Polypeptide variants that have a slightly lower level of activity compared to their wild-type versions may nevertheless be considered to be biologically active polypeptide variants. A non-limiting representative example of a biologically active polypeptide variant of the invention is a variant of FGF21, which is further modified and has similar or enhanced biological properties over wild-type FGF.
[00068] The terms "effective amount" and "therapeutically effective amount" each refer to the amount of a fusion protein of the invention used to support an observable level of one or more biological activities of polypeptide or protein homologues of the type wild, such as the ability to lower blood glucose, insulin, triglyceride or cholesterol levels; reduce levels of triglycerides or lipids in the liver; reduce body weight; or improve glucose tolerance, energy expenditure or insulin sensitivity. For example, a "therapeutically effective amount" administered to a patient who exhibits, suffers or is prone to disorders associated with FGF21 (such as type 1 or type 2 diabetes mellitus, obesity or metabolic syndrome), is such an amount that induces, attenuates or otherwise causes an improvement in pathological symptoms, disease progression, associated physical conditions or resistance to succumb to the disorders mentioned above. For the purposes of the present invention, an "individual" or "patient" is preferably a human, but can also be an animal, more specifically, a pet animal (for example, dogs, cats and the like), farm animals (for example, cows, sheep, pigs, horses and the like) and laboratory animals (for example, rats, mice, guinea pigs and the like).
[00069] The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" in this specification refers to one or more formulation materials suitable for achieving or enhancing the release of a fusion protein of the invention.
[00070] The term "antigen" refers to a molecule or part of a molecule that is capable of being linked by an antibody and that, in addition, is capable of being used in an animal to produce antibodies that are capable of becoming bind to an epitope of that antigen. An antigen can have one or more epitopes.
[00071] The term "native Fc" refers to the molecule or sequence comprising the sequence of a non-antigen-binding fragment, resulting from digestion of the entire antibody or produced by other means, whether in monomeric or multimeric form , and may contain the hinge region (of articulation). The original source of native Fc immunoglobulin is preferably of human origin and can be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Native Fc molecules are made up of monomeric polypeptides that can bind in dimeric or multimeric forms by covalent (ie, disulfide bonds) and non-covalent bonds. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on the class (for example, IgG, IgA and IgE) or subclass (for example, lgG1, lgG2, lgG3, lgA1 and lgGA2) . An example of a native Fc is a disulfide-linked dimer resulting from the papain digestion of an IgG (see Ellison et al., 1982, Nucleic Acids Res. 10: 4071-9). The term "native FC" in this specification is generic for monomeric, dimeric and multimeric forms.
[00072] The term "Fc variant" refers to a molecule or sequence that is modified from a native Fc, but which still comprises a binding site for the rescue receptor, FcRn (neonatal Fc receptor). International Publications WO 97/34631 and WO 96/32478 describe exemplary Fc variants, as well as the interaction with the rescue receiver, and are incorporated herein by reference in this patent application. Therefore, the term "Fc variant" can comprise a molecule or sequence that is humanized from a native, non-human Fc. Furthermore, a native Fc comprises regions that can be removed because they confer structural aspects or biological activity that are not necessary for the fusion molecules of the fusion proteins of the invention. Therefore, the term "Fc variant" comprises a molecule or sequence that is devoid of one or more native Fc sites or residues, or in which one or more Fc sites have been modified, affect or are involved in: (1) formation disulfide bonding, (2) incompatibility with a selected host cell, (3) heterogeneity at the N-terminus when expressed in a selected host cell, (4) glycosylation, (5) complement interaction, (6) binding to a receptor Fc other than wild-type receptor or (7) antibody-dependent cell cytotoxicity (ADCC). The Fc variants are described in more detail below.
[00073] The term "Fc domain" encompasses native Fc and Fc variants and sequences as defined above. As with Fc variants and native Fc molecules, the term "Fc domain" includes molecules in monomeric or multimeric form, whether digested from the entire antibody or produced by other means. In some embodiments of the present invention, an Fc domain can be fused to FGF21 or a mutant FGF21 (including a truncated form of FGF21 or a mutant FGF21) by, for example, a covalent bond between the Fc domain and the sequence FGF21. Such fusion proteins can form multimers through the association of the Fc domains and both these fusion proteins and their multimers represent an aspect of the present invention.
[00074] The term "modified Fc fragment" in this specification will mean an Fc fragment of an antibody comprising a modified sequence. The Fc fragment is a part of an antibody that comprises the CH2, CH3 domain and part of the hinge region. The modified Fc fragment can be derived from, for example, IgG1, IgG2, IgG3 or IgG4. FcLALA is an Fc fragment modified by a LALA mutation (L234A, L235A), which triggers ADCC with lower efficiency and weakly binds and activates the human complement. Hessell et al. 2007 Nature 449: 101-104. Additional modifications to the Fc fragment are described in, for example, U.S. Patent No. 7,217,798.
[00075] The term "heterologous" means that these domains are not naturally found associated with constant regions of an antibody. Specifically, such heterologous binding domains do not have the typical structure of a variable antibody domain consisting of 4 regions (framework), FR1, FR2, FR3 and FR4, and the 3 interspersed complementarity determining regions (CDRs). Each arm of the fused antibody (fusobody) therefore comprises a first single polypeptide chain including a first binding domain covalently linked to the N-terminal part of an antibody CH1 heavy chain constant region and a second single polypeptide chain including a second binding domain covalently linked to the N-terminal part of an LC light chain constant region of an antibody. The covalent bond can be direct, for example, through a peptide bond, or indirect through a linker, for example, a peptide linker. The two heterodimers of the fusobody are covalently linked, for example, by at least one disulfide bridge in their hinge region, similarly to the structure of an antibody. Examples of molecules with a fusobody structure have been described in the art, especially fusobodies comprising the ligand-binding region of the heterodimeric receptor (see, for example, International Patent Publications WO01 / 46261 and WO11 / 076781).
[00076] The term "polyethylene glycol" or "PEG" refers to a polyalkylene glycol compound or its derivative, with or without coupling agents or derivatization with coupling groups or activators.
[00077] The term "FGF21-associated disorders", and terms similarly used in this specification, includes obesity, type 1 and type 2 diabetes mellitus, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) , insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, kidney disease, diabetic complications, neuropathy , gastro-paresis, disorders associated with severe inactivating mutations in the insulin receptor and other metabolic disorders.
[00078] The term "disorders associated with severe inactivating mutations at the insulin receptor", and terms similarly used in this specification, describe conditions in individuals affected by mutations in the insulin receptor (or in possible proteins directly downstream of it) that cause severe insulin resistance, but which are often (though not always) seen without the common obesity in type 2 diabetes mellitus. In many ways, individuals affected by these conditions manifest hybrid symptoms of type 1 diabetes and type 2 diabetes mellitus. Individuals The affected individuals fall into several categories of more or less increasing severity, including: Type A insulin resistance, type C insulin resistance (HAIR-AN syndrome), Rabson-Mendenhall syndrome and finally Donohue syndrome or leprechaunism. These disorders are associated with very high endogenous insulin levels and, very often, with hyperglycemia. Thus, affected individuals also have a number of clinical features associated with "insulin toxicity", including hyperandrogenism, polycystic ovary syndrome (PCOS), hirsutism and acanthosis nigricans (excessive growth and pigmentation) in the skin folds.
[00079] "Type 2 diabetes mellitus" is a condition characterized by excessive glucose production despite the availability of insulin, and circulating glucose levels remain excessively high as a result of inadequate glucose clearance.
[00080] "Type 1 diabetes mellitus" is a condition characterized by high blood glucose levels caused by the total absence of insulin. This condition occurs when the body's immune system attacks the insulin-producing beta cells in the pancreas and destroys them. The pancreas then produces little or no insulin.
[00081] "Glucose intolerance" or impaired glucose tolerance (IGT) is a pre-diabetic state of dysglycemia that is associated with increased risk of cardiovascular pathology. The pre-diabetic condition prevents an individual from moving glucose into cells efficiently and from using it as an efficient energy source, leading to elevated blood glucose levels and some degree of insulin resistance.
[00082] "Hyperglycemia" is defined as excess sugar (glucose) in the blood.
[00083] "Hypoglycemia", also called low blood sugar, occurs when the blood glucose level decreases so much that it is not enough to provide energy for the activities of the body.
[00084] "Hyperinsulinemia" is defined as a higher than normal level of insulin in the blood.
[00085] "Insulin resistance" is defined as a state in which a normal amount of insulin produces a sub-normal biological response
[00086] "Obesity", in terms of the human individual, can be defined as that body weight greater than 20 percent above the ideal body weight for a given population (RH Williams, Textbook of Endocrinology, 1974, pp. 904-916) .
[00087] "Diabetic complications" are problems, caused by high blood glucose levels, with other functions of the body such as kidneys, nerves (neuropathies), feet (foot ulcers and poor circulation) and eyes (for example, retinopathies) . Diabetes also increases the risk of heart disease and bone and joint disorders. Other late complications of diabetes include skin problems, digestive problems, sexual dysfunction and problems with teeth and gums.
[00088] "Metabolic syndrome" can be defined as a grouping of at least three of the following signs: accumulation of abdominal fat mainly in men, waist width 40 inches (101.6 centimeters) or more; high blood sugar - at least 110 milligrams per deciliter (mg / dL) after fasting; high level of triglycerides - at least 150 mg / dL in the bloodstream; low HDL level - less than 40 mg / dl; and blood pressure of 130/85 mmHg or higher.
[00089] "Pancreatitis" is inflammation of the pancreas.
[00090] "Dyslipidemia" is a disorder of lipoprotein metabolism, including overproduction or deficiency of lipoproteins. Dyslipidemias can be manifested by elevated concentrations of total cholesterol, low-density lipoproteins (LDL) and triglycerides and decreased concentration of high-density cholesterol-lipoproteins (HDL) in the blood.
[00091] "Non-alcoholic fatty liver disease (NAFLD)" is a liver disease, not associated with alcohol consumption, characterized by fatty changes in hepatocytes.
[00092] "Non-alcoholic steatohepatitis (NASH)" is a liver disease, not associated with alcohol consumption, characterized by fatty changes in hepatocytes, accompanied by intralobular inflammation and fibrosis.
[00093] "Hypertension" or high blood pressure is a transient or sustained rise in systemic blood pressure to a level that is likely to induce cardiovascular or other adverse consequences. Hypertension was arbitrarily defined as systolic blood pressure above 140 mmHg or diastolic blood pressure below 90 mmHg.
[00094] "Cardiovascular diseases" are diseases related to the heart or blood vessels.
[00095] "Acute myocardial infarction" occurs when there is an interruption of blood supply to a part of the heart. The resulting ischemia and oxygen scarcity, if left untreated for a sufficient period of time, can cause damage or death (infarction) of the cardiac muscle tissue (myocardium).
[00096] "Peripheral arterial disease" occurs when plaque builds up in the arteries that carry blood to the head, organs and extremities. Over time, the plaque can harden and narrow the arteries, which restricts the flow of oxygen-rich blood to the organs and other parts of the body.
[00097] "Atherosclerosis" is a vascular disease characterized by lipid deposits irregularly distributed in the intima of large and medium-sized arteries, which cause the narrowing of arterial lumens and finally proceed to fibrosis and calcification. Lesions are usually focal and progress slowly and intermittently. Blood flow restriction is responsible for most clinical manifestations, which vary with the distribution and severity of the lesions.
[00098] "Stroke" is any acute clinical event, related to impaired cerebral circulation, that lasts more than 24 hours. A stroke involves irreversible damage to the brain, in which the type and severity of symptoms depend on the location and extent of brain tissue whose circulation has been compromised.
[00099] "Heart failure", also called congestive heart failure, is a condition in which the heart can no longer pump enough blood to the rest of the body.
[000100] "Coronary heart disease", also called coronary artery disease, is a narrowing of the small blood vessels that supply blood and oxygen to the heart.
[000101] "Kidney disease" or nephropathy is any disease of the kidney. Diabetic nephropathy is an important cause of morbidity and mortality in people with type 1 or type 2 diabetes mellitus.
[000102] "Neuropathies" are any diseases involving the cranial nerves or the peripheral or autonomic nervous system.
[000103] "Gastroparesis" is the weakness of gastric peristalsis, which results in delayed bowel emptying.
[000104] Critically ill patients covered by the present invention generally experience an unstable hypermetabolic state. This unstable metabolic state is due to changes in the metabolism of substrates, which can lead to relative deficiencies in some nutrients. In general, the oxidation of fat and muscles is increased.
[000105] Furthermore, critically ill patients are preferably patients who have systemic inflammatory response syndrome or respiratory distress. Reduction in morbidity means reducing the likelihood that a critically ill patient will develop additional illnesses, conditions or symptoms or reducing the severity of additional illnesses, conditions or symptoms. For example, reducing morbidity may correspond to decreasing the incidence of bacteremia or sepsis or complications associated with multiple organ failure.
[000106] In this specification, the singular forms "one", "one", "o" and "a" include references in the plural unless the content clearly dictates otherwise. Therefore, for example, the reference to "an antibody" includes a mixture of two or more of such antibodies.
[000107] In this specification, the term "approximately" refers to +/- 20%, more preferably, +/- 10% or even more preferably +/- 5% of a value.
[000108] The terms "polypeptide" and "protein" are used interchangeably and refer to a polymeric form of amino acids of any length, which may include encoded and non-encoded amino acids, naturally occurring and non-naturally occurring amino acids, chemical or biochemically modified or derivatives and polypeptides with modified peptide backbones. The term includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, methionine residues with or without N-terminal; immunologically tagged proteins with tags; and the like.
[000109] The terms "individual", "subject", "host" and "patient" are used interchangeably and refer to any individual for whom diagnosis, treatment or therapy is desired, especially human. Other subjects may include cattle, dogs, cats, guinea pigs, rabbits, rats, mice, horses and the like. In some preferred embodiments, the subject is a human being.
[000110] In this specification, the term "sample" refers to a patient's biological material. The sample analyzed by the present invention is not limited to any particular type. Samples include, as non-limiting examples, single cells, multiple cells, tumor tissues, biological fluids, biological or supernatant molecules or extracts from any of the foregoing. Examples include samples of tissue removed by biopsy, tissue removed during resection, blood, urine, lymphatic tissue, lymphatic fluid, cerebrospinal fluid, mucosa and feces. The sample used will vary based on the format of the assay, the method of detection and the nature of the tumors, tissues, cells or extracts to be analyzed. Methods for preparing samples are well known in the art and can be quickly adapted to obtain a sample that is compatible with the method used.
[000111] In this specification, the term "biological molecule" includes, among others, polypeptides, nucleic acids and saccharides.
[000112] In this specification, the term "modular" refers to a change in the quality or quantity of a gene, protein or any molecule that is inside, outside or on the surface of a cell. The change can be an increase or decrease in expression or level of the molecule. The term "modula" also includes changing the quality or quantity of a biological function / activity, including, among others, the ability to decrease blood glucose, insulin, triglyceride or cholesterol levels; reduce the levels of lipids or triglycerides in the liver; reduce body weight; and improving glucose tolerance, energy expenditure or insulin sensitivity.
[000113] In this specification, the term "modulator" refers to a composition that modulates one or more physiological or biochemical events associated with a disorder associated with FGF21, such as type 1 or type 2 diabetes mellitus or a type metabolic condition obesity. Such events include, among others, the ability to decrease blood glucose, insulin, triglyceride or cholesterol levels; reduce the levels of lipids or triglycerides in the liver; reduce body weight; and improving glucose tolerance, energy expenditure or insulin sensitivity.
[000114] "Gene product" is a biopolymeric product that is expressed or produced by a gene. A gene product can be, for example, an RNA not subjected to splicing, an mRNA, a variant of mRNA splicing, a polypeptide, a modified polypeptide after translation, a splicing variant polypeptide, etc. This term also covers biopolymeric products that are made using a RNA gene product as a model (ie RNA cDNA). A gene product can be made enzymatically, by recombination, chemically or inside a cell to which the gene is native. In some embodiments, if it is proteinaceous, the gene product exhibits biological activity. In some embodiments, if it is a nucleic acid, the gene product can be translated into a proteinaceous gene product that exhibits biological activity.
[000115] "Modulation of FGF21 activity" in this specification refers to an increase or decrease in FGF21 activity that may result, for example, from the interaction of an agent with a polynucleotide or FGF21 polypeptide, from inhibition of FGF21 transcription and / or translation (for example, through antisense or siRNA interaction with the FGF21 gene from the FGF21 transcript, through the modulation of transcription factors that facilitate FGF21 expression) and the like. For example, modulation of a biological activity refers to an increase or decrease in a biological activity. FGF21 activity can be assessed by means that include, but are not limited to, analyzing blood glucose, insulin, triglyceride or cholesterol levels in an individual, assessing FGF21 polypeptide levels, or assessing FGF21 transcription levels . Comparisons of FGF21 activity can also be made, for example, by measuring the levels of a downstream FGF21 biomarker and measuring increases in FGF21 signaling. FGF21 activity can also be assessed by measuring: cell signaling; kinase activity; glucose uptake in adipocytes; fluctuations in blood insulin, triglyceride or cholesterol levels; changes in lipid or triglyceride levels in the liver; the interactions between FGF21 and a FGF21 receptor; or phosphorylation of a FGF21 receptor. In some embodiments, phosphorylation of a FGF21 receptor can be tyrosine phosphorylation. In some embodiments, the modulation of FGF21 activity can cause the modulation of a FGF21-related phenotype.
[000116] FGF21 activity comparisons can also be performed, for example, by measuring the levels of a downstream biomarker of FGF21 and measuring increases in FGF21 signaling. FGF21 activity can also be assessed by measuring: cell signaling; kinase activity; glucose uptake in adipocytes; fluctuations in blood insulin, triglyceride or cholesterol levels; changes in lipid or triglyceride levels in the liver; interactions between FGF21 and a receptor (FGFR-1c, FGFR-2c or FGFR-3c); or phosphorylation of a FGF21 receptor. In some embodiments, phosphorylation of a FGF21 receptor can be tyrosine phosphorylation. In some embodiments, the modulation of FGF21 activity can cause the modulation of a FGF21-related phenotype.
[000117] "FGF21 downstream biomarker", in this specification, is a gene or gene product, or measurable evidence of a gene or gene product. In some embodiments, a gene or activity that is a downstream marker for FGF21 exhibits an altered level of expression or in vascular tissue. In some embodiments, a downstream marker activity is altered in the presence of a FGF21 modulator. In some embodiments, downstream markers exhibit altered levels of expression when FGF21 is affected with a FGF21 modulator of the present invention. Downstream markers of FGF21 include, but are not limited to, glucose or 2-deoxy-glucose uptake, pERK and other phosphorylated or acetylated proteins or NAD levels.
[000118] In this specification, the term "regulates positively" refers to an increase, activation or stimulation of an activity or quantity. For example, in the context of the present invention, FGF21 modulators can increase the activity of a FGF21 receptor. In one embodiment, one or more of FGFR-1c, FGFR-2c or FGFR-3c can be up-regulated in response to a FGF21 modulator. Positive regulation can also refer to an activity related to FGF21, such as, for example, the ability to decrease blood levels of glucose, insulin, triglycerides or cholesterol; reduce body weight; improve glucose tolerance, energy expenditure or insulin sensitivity; or cause phosphorylation of a FGF21 receptor; or increase a downstream FGF21 marker. The FGFR21 receptor can be one or more of FGFR-1c, FGFR-2c or FGFR-3c. Positive regulation can be at least 25%, at least 50%, at least 75%, at least 100%, at least 150%, at least 200%, at least 250%, at least 400% or at least 500% when compared to a control.
[000119] In this specification, the term "N-termination" refers to at least the first 20 amino acids of a protein.
[000120] In this specification, the terms "N-terminal domain" and "N-terminal region" are used interchangeably and refer to a fragment of a protein that starts at the first amino acid in the protein and ends at any amino acid in the middle of N -terminal of the protein. For example, the N-terminal domain of FGF21 is from amino acid 1 of SEQ ID NO: 1 to any amino acid between amino acids 10 and 105 of SEQ ID NO: 1.
[000121] In this specification, the term "C-termination" refers to at least the last 20 amino acids of a protein.
[000122] In this specification, the terms "C-terminal domain" and "C-terminal region" are used interchangeably and refer to a fragment of a protein that starts at any amino acid in the C-terminal half of the protein and ends at the last amino acid in the protein. For example, the FGF21 C-terminal domain starts at any amino acid from amino acid 105 to approximately amino acid 200 of SEQ ID NO: 1 and ends at amino acid 209 of SEQ ID NO: 1.
[000123] The term "domain" in this specification refers to a structural part of a biomolecule that contributes to a known or suspected function of the biomolecule. Domains can cover regions or parts of these and can also incorporate a part of a biomolecule that is distinct from a particular region, in addition to all or part of that region.
[000124] In this specification, the term "signaling domain" (also called "signaling sequence" or "signaling peptide") refers to a peptide domain that is located in a continuous section of an amino acid sequence in the region N-terminal of a precursor protein (often a membrane-bound or secreted protein) and is involved in transport after protein translation. In many cases, the signaling domain is removed from the complete protein by specialized signaling peptidases after the separation process has been completed. Each signaling domain specifies a specific target in the cell for the precursor protein. The FGF21 signaling domain is represented by amino acids 1-28 of SEQ ID NO: 1.
[000125] In this specification, the term "receptor binding domain" refers to any part or region of a protein that contacts a membrane-bound receptor protein, resulting in a cellular response, such as a signaling event.
[000126] In this specification, the term "ligand-binding domain" refers to any part or region of a fusion protein of the invention that retains at least one qualitative binding activity of a corresponding native sequence.
[000127] The term "region" refers to a physically contiguous part of the primary structure of a biomolecule. In the case of proteins, a region is defined by a contiguous part of that protein's amino acid sequence. In some embodiments, a "region" is associated with a function of the biomolecule.
[000128] The term "fragment" in this specification refers to a physically contiguous part of the primary structure of a biomolecule. In the case of proteins, a part is defined by a contiguous part of the amino acid sequence of that protein, and this refers to at least 3-5 amino acids, at least 8-10 amino acids, at least 11-15 amino acids, at least 17- 24 amino acids, at least 25-30 amino acids and at least 30-45 amino acids. In the case of oligonucleotides, a part is defined by a contiguous part of the nucleic acid sequence of that oligonucleotide and refers to at least 915 nucleotides, at least 18-30 nucleotides, at least 33-45 nucleotides, at least 48 -72 nucleotides, at least 75-90 nucleotides and at least 90-130 nucleotides. In some embodiments, parts of biomolecules have biological activity. In the context of the present invention, FGF21 polypeptide fragments do not comprise the entire FGF21 polypeptide sequence shown in SEQ ID NO: 1.
[000129] A "native sequence" polypeptide is one that has the same amino acid sequence as a polypeptide derived from nature. Such native sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. Therefore, a polypeptide with native sequence may have the amino acid sequence of the naturally occurring human polypeptide, the murine polypeptide, or the polypeptide of any other species of mammal.
[000130] In this specification, the expression "homologous nucleotide sequence" or "homologous amino acid sequence", or its variations, refers to sequences characterized by a homology, at the nucleotide or amino acid level, of at least one specified percentage and is used interchangeably with "string identity". Homologous nucleotide sequences include those sequences that encode protein isoforms. Such isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative RNA splicing. Alternatively, isoforms can be encoded by different genes. Homologous nucleotide sequences include nucleotide sequences that encode a protein from another species other than human, including, among others, mammals. Homologous nucleotide sequences also include, among others, naturally occurring allelic variations and mutations in the nucleotide sequences presented in this specification. Homologous amino acid sequences include those amino acid sequences that contain conservative amino acid substitutions and whose polypeptides have the same bond and / or activity. In some embodiments, a sequence of nucleotides or amino acids is homologous if it has at least 60% or more up to 99% identity with a comparator sequence. In some embodiments, a nucleotide or amino acid sequence is homologous if it shares one or more, going up to 60, nucleotide / amino acid substitutions, additions or deletions with a comparator sequence. In some embodiments, homologous amino acid sequences have a maximum of 5 or a maximum of 3 conservative amino acid substitutions.
[000131] The percentage of homology or identity can be determined, for example, by the Gap program (Wisconsin Sequence Analysis Package, Version 8 of UNIX, Genetics Computer Group, University Research Park, Madison, Wl), using standard settings, which employs the Smith and Waterman algorithm (Adv. Appl. Math., 1981, 2, 482-489). In some embodiments, the homology between the probe and the target is between approximately 75% and approximately 85%. In some embodiments, nucleic acids have nucleotides that are approximately 95%, approximately 97%, approximately 98%, approximately 99% and approximately 100% homologous to SEQ ID NO: 2, or a part thereof.
[000132] Homology can also be at the peptide level. In some embodiments, the polypeptides constituting the fusion proteins of the invention can be at least 95% homologous to their complete wild-type versions or corresponding native sequences, or parts thereof. The degree or percentage of identity of the fusion proteins of the invention, or parts thereof, and different sequences of amino acids is calculated as the number of exact hits in an alignment of the two sequences divided by the length of the "invention sequence" or " strange sequence ", whichever is shorter. The result is expressed as a percentage of identity.
[000133] In this specification, the term "mix" refers to the process of combining one or more compounds, cells, molecules and the like together in the same area. The mixing can be carried out, for example, in a test tube, Petri dish or any container that allows one or more compounds, cells or molecules to be mixed.
[000134] In this specification, the term "substantially purified" refers to a compound (for example, a polynucleotide, polypeptide or an antibody) that is removed from its natural environment and is free by at least 60%, free in at least 75% and free in at least 90% of the other components with which it is naturally associated.
[000135] The term "pharmaceutically acceptable carrier" refers to a carrier for the administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of harmful antibodies to the individual receiving the composition, and that can be administered without undue toxicity. Suitable vehicles can be large macromolecules, slowly metabolized as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates and inactive viral particles. Such vehicles are well known to those skilled in the art. Pharmaceutically acceptable vehicles in therapeutic compositions can include liquids, such as water, saline, glycerol and ethanol. Auxiliary substances, such as moisturizing or emulsifying agents, pH buffering substances and the like can also be present in such vehicles.
[000136] Improvement of the physical stability of the fusion proteins of the invention
[000137] Naturally occurring disulfide bonds, as provided by cysteine residues, generally increase the thermodynamic stability of proteins. Successful examples of increased thermodynamic stability, as measured in increasing melting temperature, are mutants with multiple disulfide bonds of the enzymes T4 lysozyme (Matsumura et al., PNAS 86: 6562-6566 (1989)) and barnase (Johnson et al ., J. Mol. Biol. 268: 198-208 (1997)). One aspect of the present invention is an improvement in the physical stability of FGF21 in the presence of a preservative, achieved by the presence of disulfide bonds within the variants, which restricts the flexibility of wild-type FGF21 and thus limits the access of the preservative to the hydrophobic core of the protein.
[000138] The second aspect of the present invention, therefore, provides variants of human FGF21, or a biologically active peptide thereof, with enhanced pharmaceutical stability generated by the incorporation of additional disulfide bonds, for example, by incorporating or replacing cysteine residues in the wild-type FGF21 protein or in the polypeptide or protein variants of the invention. The person skilled in the art will recognize that native cysteines, cysteine 103 and cysteine 121, could be used as the locus for introducing a new disulfide bond that can impart improved properties, in addition to the embodiments suggested and described in this patent application.
[000139] These include fusion proteins that incorporate wild-type FGF-21 with the replacement of two or more of the following amino acids with cysteine: glutamine 46, arginine 47, tyrosine 48, leucine 49, tyrosine 50, threonine 51, aspartate 52, aspartate 53, alanine 54, glutamine 55, glutamine 56, threonine 57, glutamate 58, alanine 59, histidine 60, leucine 61, glutamate 62, isoleucine 63, valine 69, glycine 70, glycine 71, alanine 72, alanine 73, leucine 144, histidine 145, leucine 146, proline 147, glycine 148, asparagine 149, lysine 150, serine 151, proline 152, histidine 153, arginine 154, aspartate 155, proline 156, alanine 157, proline 158, arginine 159 , glycine 160, proline 161, alanine 162, arginine 163, phenylalanine 164, in which the numbering of amino acids is based on the complete sequence of hFGF21, SEQ ID NO: 1, formed by 209 amino acids.
[000140] Furthermore, the fusion proteins of the invention that may incorporate variants of human wild-type FGF21, or a biologically active peptide thereof, and enhanced with constructed disulfide bonds, in addition to that of naturally occurring Cys103-Cys121, are as follows: Gln46Cys-Ala59Cys, Gln46Cys-His60Cys, Gln46Cys-Leu61Cys, Gln46Cys-Glu62Cys, Gln46Cys-lle63Cys, Arg47Cys-Ala59Cys, Arg47Cys-His60Cys, Arg47Cys-LeuuCys-Arg, 47Cys-Arg, 47 , Tyr48Cys-Leu61Cys, Tyr48Cys-Glu62Cys, Tyr48Cys-lle63Cys, Leu49Cys-Ala59Cys, Leu49Cys-His60Cys, Leu49Cys-Leu61Cys, Leu49Cys-Glu62Cys, TyrCys-TysCys-TleCys, Tyr48Cys-T50 -lle63Cys, Leu144Cys-Gly160Cys, Leu144Cys-Pro161Cys, Leu144Cys-Ala162Cys, Leu144CysArg163Cys, Leu144Cys-Phe164Cys, His145Cys-Gly160Cys, Pro161Cys-His145Cys, His145Cys-Ala162Cys, His145Cys-Arg163Cys, Phe164Cys-His145Cys, Leu146Cys-Gly160Cys, Leu146 CysPro161Cys, Leu146Cys-Ala162Cys, Leu146Cys-Arg163Cys, Leu146Cys-Phe164Cys, Pro147Cys-Gly160Cys, Pro147CysPro161Cys, Pro147Cys-Ala162Cys, Pro147Cys-Arg163Cys, Pro147Cys-Phe164Cys, Gly148Cys-Gly160Cys, Gly148CysPro161Cys, Gly148Cys-Ala162Cys, Gly148Cys-Arg163Cys, Gly148Cys-Phe164Cys, Thr57Cys-Val69Cys, Thr57Cys-Gly70Cys, Thr57Cys-Gly71Cys, Thr57Cys-Ala72Cys, Thr57Cys-Ala73Cys, Glu58Cys-Val69Cys, Glu58Cys-Glu70Cys, Glu58Cys-G71Cys, Glu58Cys-Ala, Glu58Cys-Ala72 Gly71Cys, Ala59Cys-Ala72Cys, Ala59Cys-Ala73Cys, His60Cys-Val69Cys, His60Cys-Gly70Cys, His60Cys-Gly71Cys, His60Cys-Ala72Cys, His60Cys-Ala73Cys, Leu61Cys-Le69Sys, GlyCys, Le6161 Arg47Cys-Gly148Cys, Tyr48Cys-Gly148Cys, Leu49Cys-Gly148Cys, Tyr50Cys-Gly148Cys, Thr51Cys-Gly148Cys, Asp52Cys-Gly148Cys, Gly148Cys-Asp53Cys, Ala54Cys-Gly148Cys, Gln55Cys-Gly148Cys, Gln56Cys-Gly148Cys, Thr57Cys-Gly148Cys, Glu58Cys-Gly148Cys, Ar g47Cys-Asn149Cys, Tyr48Cys-Asn149Cys, Leu49Cys-Asn149Cys, Tyr50Cys-Asn149Cys, Thr51Cys-Asn149Cys, Asn149Cys-Asp52Cys, Asn149Cys-Asp53Cys, Ala54Cys-Asn149Cys, Gln55Cys-Asn149Cys, Gln56Cys-Asn149Cys, Thr57Cys-Asn149Cys, Glu58Cys-Asn149Cys, Arg47Cys- Lys150Cys, Tyr48Cys-Lys150Cys, Leu49Cys-Lys150Cys, Tyr50Cys-Lys150Cys, Thr51Cys-Lys150Cys, Asp52Cys-Lys150Cys, Asp53Cys-Lys150Cys, Ala54Cys-Lys150Cys, Gln55Cys-Lys150Cys, Gln56Cys-Lys150Cys, Thr57Cys-Lys150Cys, Glu58Cys-Lys150Cys, Arg47Cys-Ser151Cys, Tyr48Cys-Ser151Cys, Leu49Cys-Ser151Cys, Tyr50Cys-Ser151Cys, Thr51Cys-Ser151Cys, Asp52Cys-Ser151Cys, Asp53Cys-Ser151Cys, Ala54Cys-Ser151Cys, Gln55Cys-Ser1Cys-Ser1Cys-Gl1555Cys-Gl1555Cys-Gl15 Pro152Cys, Leu49Cys-Pro152Cys, Tyr50Cys-Pro152Cys, Thr51Cys-Pro152Cys, Asp52Cys-Pro152Cys, Asp53Cys-Pro152Cys, Ala54Cys-Pro152Cys, Gln55Cys-Pro152ys, Gln56Cys-Pro, Gln56Cys-15, Le u49Cys-His153Cys, Tyr50Cys-His153Cys, Thr51Cys-His153Cys, Asp52Cys-His153Cys, Asp53Cys-His153Cys, Ala54Cys-His153Cys, Gln55Cys-His15ysCys-His153Cys, His153Cys, Thr57Cys-His153Cys, Thr57Cys Arg154Cys, Tyr50Cys-Arg154Cys, Thr51Cys-Arg154Cys, Asp52Cys-Arg154Cys, Asp53Cys-Arg154Cys, Ala54Cys-Arg154Cys, Gln55Cys-Arg154Cys, Gln56Cys-Arg154Cys, Thr57Cys-Arg154Cys, Glu58Cys-Arg154Cys, Arg47Cys-Asp155Cys, Tyr48Cys-Asp155Cys, Leu49Cys-Asp155Cys, Tyr50Cys-Asp155Cys, Thr51Cys-Asp155Cys, Asp155Cys-Asp52Cys, Asp155Cys-Asp53Cys, Ala54Cys-Asp155Cys, Gln55Cys-Asp155Cys, Gln56Cys-Asp155Cys, Thr57Cys-Asp155Cys, Glu58Cys-Asp155Cys, Arg47Cys-Pro156Cys, Tyr48Cys-Pro156Cys, Leu49Cys-Pro156Cys, Tyr50Cys- Pro156Cys, Thr51Cys-Pro156Cys, Asp52Cys-Pro156Cys, Asp53Cys-Pro156Cys, Ala54Cys-Pro156Cys, Gln55Cys-Pro156Cys, Gln56Cys-Pro156Cys, Thr57Cys-Pro156Cys, Glu58Cys-Pro156Cys, Arg47Cys-Ala157Cys, Tyr48Cys-Ala157Cys, Leu49Cys-Ala157Cys, Tyr50Cys-Ala157Cys, Th r51Cys-Ala157Cys, Asp52Cys-Ala157Cys, Ala157Cys-Asp53Cys, Ala54Cys-Ala157Cys, Gln55Cys-Ala157Cys, Gln56Cys-Ala157Cys, Thr57Cys-Ala157Cys, Glu58Cys-Ala157Cys, Arg47Cys-Pro158Cys, Tyr48Cys-Pro158Cys, Leu49Cys-Pro158Cys, Tyr50Cys-Pro158Cys, Thr51Cys- Pro158Cys, Asp52Cys-Pro158Cys, Asp53Cys-Pro158Cys, Ala54Cys-Pro158Cys, Gln55Cys-Pro158Cys, Gln56Cys-Pro158Cys, Thr57Cys-Pro158Cys, Glu58Cys-Pro158ys, Arg47Cys-Arg159, Arg47Cys-Arg159, Arg47Cys-Arg159 Asp52Cys-Arg159Cys, Asp53Cys-Arg159Cys, Ala54Cys-Arg159Cys, Gln55Cys-Arg159Cys, Gln56Cys-Arg159Cys, Thr57Cys-Arg159Cys, Glu58Cys-Arg159Cys, Arg47Cys-G160Cys, G160Cys-T60 Gly160Cys, Asp53Cys-Gly160Cys, Ala54Cys-Gly160Cys, Gln55Cys-Gly160Cys, Gln56Cys-Gly160Cys, Thr57Cys-Gly160Cys, Glu58Cys-Gly160Cys, Arg47Cys-Pro161Cys, Tyr48Cys-Pro161Cys, Leu49Cys-Pro161Cys, Tyr50Cys-Pro161Cys, Thr51Cys-Pro161Cys, Asp52Cys-Pro161Cys, Asp53Cys -Pro161Cys, Ala54Cys-Pro161Cys, Gln55Cys-Pro161Cys, Gln56Cys-Pro161Cys, Thr57Cys-Pro161Cys, Glu58Cys-Pro161Cys, Arg47Cys-Ala162Cys, Tyr48Cys-Ala162Cys, Leu49Cys-Ala162Cys, Tyr50Cys-Ala162Cys, Thr51Cys-Ala162Cys, Asp52Cys-Ala162Cys, Asp53Cys-Ala162Cys , Ala54Cys-Ala162Cys, Gln55Cys-Ala162Cys, Gln56Cys-Ala162Cys, Thr57Cys-Ala162Cys, Glu58Cys-Ala162Cys, Arg47Cys-Arg163Cys, Tyr48Cys-Arg163Cys, Leu49Cys-Arg163Cys, Tyr50Cys-Arg163Cys, Thr51Cys-Arg163Cys, Asp52Cys-Arg163Cys, Asp53Cys-Arg163Cys, Ala54Cys -Arg163Cys, Gln55Cys-Arg163Cys, Gln56Cys-Arg163Cys, Thr57Cys-Arg163Cys, Glu58Cys-Arg163Cys.
[000141] Another aspect of the present invention provides fusion proteins that comprise variants of human wild-type FGF21, or a biologically active peptide thereof, containing a replacement for any charged and / or polar, but uncharged amino acid, in any of the positions of amino acids indicated in the first embodiment of the present invention, combined with the replacement of a cysteine in two or more amino acid positions indicated in the second embodiment of the invention.
[000142] Improvement of the fusion proteins of the invention above comparator proteins of the wild type and their variants
[000143] It is well known in the art that a considerable challenge in the development of protein pharmaceutical substances is dealing with the physical and chemical stability of proteins. This challenge is even more evident when a pharmaceutical protein formulation is intended for a multiple use injectable formulation that requires a stable, concentrated and preserved solution, while maintaining a favorable bioactivity profile. The biophysical characterization of wild-type FGF21 in the literature established that a concentrated protein solution (> 5 mg / mL), when exposed to stress conditions, such as high temperature or low pH, leads to accelerated association and aggregation (ie, low physical stability and biopharmaceutical properties). The exposure of a concentrated protein solution of FGF21 to pharmaceutical preservatives (for example, m-cresol) also has a negative impact on physical stability.
[000144] Therefore, an embodiment of the present invention is to reinforce the physical stability of concentrated solutions, while maintaining chemical stability and biological potency, under physiological and formulation conditions with preservatives. It is believed that association and aggregation may result from hydrophobic interactions, since at a given protein concentration, temperature and ionic strength have a considerable impact on physical stability. Most of the time, the targets are residues of unconserved amino acids, supposedly exposed on the surface. The local environment of these residues was analyzed, and those, not considered structurally important, were selected for mutagenesis. One method for initiating specific changes is to further decrease the protein's pI by introducing glutamic acid residues ("glutamic acid scan"). It is postulated that the introduction of charged substitutes would inhibit the aggregation of hydrophobic mediation via charge-charge repulsion and potentially improve compatibility with the preservative. Additionally, the technician in the subject would also recognize that, with a sufficient degree of mutagenesis, the pI could deviate to a basic pH range by introducing a positive charge without or with the concomitant decrease in negative charge, thus allowing charge-charge repulsion.
[000145] An additional difficulty associated with therapeutic applications of wild-type FGF21 as a biotherapeutic agent, for example, is that its half-life is very short in vivo (in the order of 0.5 and 2 h, respectively, in mouse and primate ). There is therefore a need to develop tracking compounds that are more effective, either through higher power or longer half-life. The fusion proteins of the invention were developed as a way to achieve the desirable effects of treatment with FGF21 at a higher potency and in an extended half-life formulation.
[000146] As described in more detail in this patent application, the half-life of the fusion proteins of the invention is greater than two weeks in the mouse, when compared to the shorter half-life of wild-type FGF21 and the half-life of 17 hours of the Fc-L (15) -FGF21 fusion protein (L98R, P171G, A180E) in PCT Publication WO10 / 129600. The fusion proteins of the invention also demonstrate improved half-life and pharmacokinetic properties when compared to PEGylated V76, as described in this patent application and in US Patent Application 61/415 476, filed on November 19, 2010.
[000147] Furthermore, the Fc-FGF21 fusion proteins of the invention at 1 mpk are more effective than V76 at 5 mpk in reducing glucose, insulin, body weight and lipid in the liver. In a 12-day treatment study in ob / ob mice, the fusion proteins showed the following% changes from the vehicle (all fusions are administered at 1.0 mg / kg, and V76 is administered at 5.0 mg / kg):% change in total glucose (AUC) in relation to the vehicle: V76 equal to -42%; V101 equal to -53%, V103 equal to -46% and V188 equal to -42%; % change in total plasma insulin in relation to the vehicle: V76 equal to -46%; V101 equal to -82%, V103 equal to -69% and V188 equal to -59%; % change in total body weight in relation to the vehicle: V76 equal to -7%; V101 equal to -12%, V103 equal to -12% and V188 equal to -11%; and% change in total lipids in the liver in relation to the vehicle: V76 equal to -30%; V101 equal to -44%, V103 equal to - 50% and V188 equal to -51%. Likewise, in vitro assays revealed the same potency 5 times greater or greater than the fusion proteins of the invention above V76: In the pERK assay in human adipocytes (mean EC50 ± SEM), the V76 value is 21 ± 2 nM ( n = 3); V101 is 1.0 ± 0.1 nM (n = 3), V103 is 1.3 ± 0.2 nM (n = 3) and V188 is 1.4 ± 0.4 nM (n = 3) ; In the HEK293 pERK assay with human β-klotho (mean EC50 ± SEM), the value of V76 is 13 ± 4 nM (n = 5), of V101 it is 0.60 ± 0.06 nM (n = 5), V103 is 0.9 ± 0.3 nM (n = 5) and V188 is 0.4 ± 0.1 nM (n = 3); e In the glucose uptake assay in mouse adipocytes (mean EC50 ± SEM), the value of V76 is 5 ± 1 nM (n = 3), of V101 it is 0.60 ± 0.06 nM (n = 3), V103 is 0.60 ± 0.07 nM (n = 3) and V188 is 0.48 ± 0.14 nM (n = 3).
[000148] Although the embodiments of the present invention concern physical and chemical stability under physiological and formulation conditions with preservatives, maintaining the biological potency of the fusion proteins of the invention when compared to, for example, wild-type FGF21, is a important consideration factor as well. Therefore, the biological potency of the proteins of the present invention is defined by the ability of proteins to affect glucose uptake and / or to reduce plasma glucose levels, as shown in the examples here.
[000149] The proteins, polypeptides and / or peptides of the invention administered in accordance with this invention can be generated and / or isolated by any means known in the art. The most preferred method for producing the variant is through recombinant DNA methodologies and is well known to those skilled in the art. Such methods are described in Current Protocols in Molecular Biology (John Wiley & Sons, Inc.), incorporated herein by reference in this patent application.
[000150] In addition, preferred embodiments include a biologically active peptide derived from the variant described herein. Such a peptide will contain at least one of the described substitutions and the variant will have biological activity. The peptide can be produced by any and all means known to those skilled in the art, examples of which include, among others, enzymatic digestion, chemical synthesis or recombinant DNA methodologies.
[000151] In the art, it is established that peptide fragments of certain fibroblast growth factors are biologically active. See, for example, Baird et al., Proc. Natl. Acad. Sci (USA) 85: 2324-2328 (1988) and J. Cell. Phys. Suppl. 5: 101-106 (1987). Consequently, the selection of fragments or peptides of the variant is based on criteria known in the art. For example, dipeptidyl peptidase IV (DPP-IV or DPP-4) is known to be a serine-like protease involved in inactivating neuropeptides, endocrine peptides and cytokines (Damme et al., Chem. Immunol. 72: 42-56, (1999)). The N-terminal of FGF21 (HisProllePro) contains two dipeptides that could be substrates for DPP-IV, resulting in a fragment of FGF21 truncated at the N-terminal by 4 amino acids. Unexpectedly, this wild-type FGF21 fragment has been shown to retain biological activity, so proteins of the present invention truncated at the N-terminus to up to 4 amino acids is an embodiment of the present invention.
[000152] The invention also encompasses polynucleotides that encode the variants described above, which can be in the form of RNA or in the form of DNA, wherein DNA includes cDNA, genomic DNA and synthetic DNA. DNA can be double-stranded or single-stranded. The coding sequences that encode the proteins of the present invention may vary as a result of redundancy or degeneration of the genetic code.
[000153] Polynucleotides encoding the fusion proteins of the invention may include the following: only the variant coding sequence, the variant coding sequence and additional coding sequence, such as a functional polypeptide or a leader or secretory sequence or a sequence of pro-protein; the variant coding sequence and a non-coding sequence, such as introns or 5 'and / or 3' non-coding sequence of the variant coding sequence. Accordingly, the term "polynucleotide encoding a variant" embraces a polynucleotide that can include not only the coding sequence for the variant, but also a polynucleotide that includes an additional coding and / or non-coding sequence.
[000154] The invention also relates to variants of the described polynucleotides that encode fragments, analogs and derivatives of the polypeptide that contain the indicated substitutions. The polynucleotide variant can be a naturally occurring allelic variant of the human FGF21 sequence, a non-naturally occurring variant, or a truncated variant as described above. Accordingly, the present invention also includes polynucleotides encoding the variants described above, as well as variants of such polynucleotides, which variants encode a fragment, derivative or analog of the described variant. Such nucleotide variants include deletion variants, substitution variants, truncated variants and addition or insertion variants, provided that at least one of the indicated amino acid substitutions of the first or second embodiment is present.
[000155] The polynucleotides of the invention will be expressed in hosts after the sequences have been operationally linked to an expression control sequence (i.e., positioned to ensure their functioning). These expression vectors are typically capable of replication in host organisms, either as episomes or as an integral part of the host's chromosomal DNA. In common, the expression vectors will contain selection markers, for example, tetracycline, neomycin and dihydrofolate reductase, to allow the detection of those cells transformed with the desired DNA sequences. The FGF21 variant can be expressed in mammalian, insect, yeast, bacterial or other cells under the control of appropriate promoters. Free translation systems in cells can also be employed to produce such proteins that make use of RNAs derived from DNA constructs of the present invention.
[000156] E. coli is a prokaryotic host especially useful for cloning the polynucleotides of the present invention. Other microbial hosts suitable for use include Bacillus subtilus, Salmonella typhimurium and several species of Serratia, Pseudomonas, Streptococcus and Staphylococcus, although others may also be employed as the materials of choice. In these prokaryotic hosts, it is also possible to produce expression vectors, which will typically contain expression control sequences compatible with the host cell (for example, an origin of replication). In addition, any of a number of well-known promoters can be present, such as lactose promoter system, tryptophan (Trp) promoter system, beta-lactamase promoter system or promoter system derived from lambda or T7 phages. Promoters will typically control expression, optionally with an operator sequence, and will have sequences of ribosome-binding sites and the like, to initiate and complete transcription and translation.
[000157] The person skilled in the art of protein expression will recognize that the methionine or methionine-arginine sequence can be introduced at the N-terminus of the mature sequence (SEQ ID NO: 3) for expression in E. coli and these are contemplated within of the context of this invention. Therefore, unless otherwise noted, the proteins of the present invention expressed in E. colipose have a methionine sequence introduced at the N-terminus.
[000158] Other microbes, such as yeasts or fungi, can also be used for expression. Pichia pastoris, Saccharomyces ce-revisiae, Schizosaccharomyces pombe and Pichia angustasão examples of preferred yeast-like hosts, with suitable vectors containing expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin replication, termination sequences and the like as desired. Aspergillus niger, Trichoderma reesei and Schizophyllum common are examples of fungus-type hosts, although others can be used as the material of choice.
[000159] Cell culture of mammalian tissues can also be used to express and produce the polypeptides of the present invention. Eukaryotic cells are currently preferred because a number of suitable host cell lines capable of secreting intact variants have been developed, and these include CHO cell lines, various COS cell lines, NSO cells, Syrian hamster ovary cell lines , HeLa cells or human embryonic kidney cell lines (ie HEK293, HEK293EBNA).
[000160] The expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer, and the sites needed for processing information, such as ribosome binding sites. - mos, RNA splicing sites, polyadenylation sites and transcription terminator sequences. Preferred expression control sequences are promoters derived from SV40, adenovirus, bovine patiloma virus, cytomegalovirus, Raus sarcoma virus and the like. Preferred polyadenylation sites include sequences derived from SV40 and bovine growth hormone.
[000161] Vectors containing the polynucleotide sequences of interest (for example, the fusion proteins of the invention and expression control sequences) can be transferred to the host cell by well-known methods, which vary depending on the type of cell host. For example, calcium chloride-mediated transfection is commonly used for prokaryotic cells, while treatment with calcium phosphate or electroporation can be used for other cell hosts.
[000162] Various methods of protein purification can be employed and such methods are known in the art and are described, for example, in Deutscher, Methods in Enzymology 182: 83-9 (1990) and Scopes, Protein Purification: Principles and Practice, SpringerVerlag, NY (1982). The selected purification steps will depend, for example, on the nature of the production process used for the fusion proteins of the invention.
[000163] The proteins, polypeptides and / or peptides of the invention, for example, the dual activity fusion proteins of the invention, must be formulated and administered in a manner compatible with good medical practice, taking into account the clinical condition of the patient, the site of release of protein compositions, the mode of administration, the schedule of administration and other factors known to practitioners. The "therapeutically effective amount" of the fusion proteins of the invention for the purposes of the present is thus determined by such considerations.
[000164] The pharmaceutical compositions of the proteins of the present invention can be administered by any means that achieve the general objective intended: treating type 1 and type 2 diabetes mellitus, obesity, metabolic syndrome or critically ill patients. Permitted non-limiting means of administration include, for example, by inhalation or suppository or to mucous tissue, such as by washing the vaginal, rectal, urethral, buccal and sublingual tissue, orally, nasal, topical, intranasal, intraperitoneal , parenteral, intravenous, intramuscular, intrasternal, by intra-articular, intralymphatic, interstitial, intra-arterial, subcutaneous, intrasynovial, transepithelial and transdermal injection. In some embodiments, the pharmaceutical compositions are administered by washing, orally or intraarterially. Other suitable modes of introduction may also include refillable or biodegradable devices and polymeric devices for slow or sustained release. The pharmaceutical compositions of this invention can also be administered as part of a combination therapy with other known metabolic agents.
[000165] The dose administered will depend on the age, health and weight of the recipient, the type of concomitant treatment, if any, the frequency of treatment and the nature of the desired effect. Compositions within the scope of the invention include all compositions in which a variant of FGF21 is present in an amount that is effective in achieving the desired medical effect in the treatment of type 1 or type 2 diabetes mellitus, obesity or metabolic syndrome. Although individual needs may vary from one patient to another, determining the ideal ranges of effective amounts for all components is within the reach of the clinician with common competence.
[000166] The proteins of the present invention can be formulated according to known methods for preparing pharmaceutically useful compositions. A desired formulation would be one that is a stable lyophilized product that is reconstituted with an appropriate diluent or a high purity aqueous solution with optional pharmaceutically acceptable vehicles, preservatives, excipients or stabilizers [Remington's Pharmaceutical Sciences, 16th edition (1980)]. The proteins of the present invention can be combined with a pharmaceutically acceptable buffer, and the pH adjusted to provide acceptable stability and an acceptable pH for administration.
[000167] For parenteral administration, in one embodiment, the fusion proteins of the invention are generally formulated by mixing one or more of these to the desired degree of purity, in an injectable unit dose form (solution, suspension or emulsion), with a pharmaceutically acceptable vehicle, that is, one that is not toxic to the receptors at the doses and concentrations used and that is compatible with other ingredients of the formulation. Preferably, one or more pharmaceutically acceptable antimicrobial agents can be added. Phenol, m-cresol and benzyl alcohol are preferred pharmaceutically acceptable microbial agents.
[000168] Optionally, one or more pharmaceutically acceptable salts can be added to adjust ionic strength or tonicity. One or more excipients can be added to further adjust the isotonicity of the formulation. Glycerin, sodium chloride and mannitol are examples of excipients for adjusting isotonicity.
[000169] Those skilled in the art can rapidly improve pharmaceutically effective doses and delivery schedules for therapeutic compositions comprising the proteins of the invention, as determined by good medical practice and the individual clinical condition of the patient. A typical dose range for the proteins of the present invention will range from approximately 0.01 mg per day to approximately 1000 mg per day (or approximately 0.05 mg per week to approximately 5000 mg per week, administered once a week) for an adult. Preferably, the dose ranges vary from approximately 0.1 mg per day to approximately 100 mg per day (or from approximately 0.5 mg per week to approximately 500 mg per week, administered once a week), more preferably approximately 1.0 mg / day to approximately 10 mg / day (or approximately 5 mg per week to approximately 50 mg per week, administered once a week). More preferably, the dose is approximately 1-5 mg / day (or approximately 5 mg per week to approximately 25 mg per week, administered once a week). The appropriate dose of a FGF21 variant administered will result in reduced blood glucose levels and increased energy expenditure due to faster and more efficient use of glucose and, therefore, is useful for treating type 1 and type 2 diabetes mellitus, obesity and metabolic syndrome.
[000170] In addition, because hyperglycemia and insulin resistance are common in critically ill patients who are provided with nutritional support, some intensive care units administer insulin for excessive hyperglycemia in critically ill fed patients. In fact, recent studies document the use of exogenous insulin to keep blood glucose at a maximum level of 110 mg per deciliter and to reduce morbidity and mortality among critically ill patients in the surgical intensive care unit, regardless of whether they have a history or not. of diabetes (Van den Berghe et al., N Engl J Med., 345 (19): 1359, (2001)). Accordingly, the proteins of the present invention are uniquely suited to help restore metabolic stability in critically ill patients unstable metabolically. Proteins of the invention, such as those that contain variants of FGF21, are unique in that they stimulate glucose uptake and improve insulin sensitivity, but do not induce hypoglycemia.
[000171] In another aspect of the present invention, the use of proteins of the invention is contemplated as a medicine for the treatment of obesity, type 1 and type 2 diabetes mellitus, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), steatohepati - non-alcoholic (NASH), insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute myocardial infarction, conditions associated with severe inactivating mutations in the insulin receptor and other metabolic disorders. FGF21 site-specific mutants
[000172] In some embodiments, the fusion proteins of the invention include additional FGF21 mutants or FGF21 analogs with unnatural amino acids.
[000173] In some embodiments, the fusion proteins of the invention comprise FGF21 agonists with one or more of the following additional wild-type FGF21 modifications: additional disulfides, unnatural amino acids or modifications to promote dimerization, such as the formation of a disulfide at R154C or the introduction of a cysteine elsewhere, dimerization through a fused Fc domain or the formation of dimers through a crosslinker such as a bifunctional PEG; FGF21 fragments; proteins selected to have FGF21 activity (binding to beta-klotho and binding and activation of its FGFR); and a FGF21 mimetic antibody (of various formats such as Fab, unibody, svFc, etc.).
[000174] In some embodiments, the fusion proteins of the invention comprise one or more of the following ligands: single amide bond, short peptides (especially Ser / Gly repeats), additional residues of the translated FGF21 sequence or a larger linker to a protein whole (such as an Fc domain, a helix beam connecting to the HSA, HSA, etc.). The two groups can also be linked by other chemical means, such as through unnatural amino acids or standard chemical linkers (maleimide-Cys, NHS-Lys, click, etc.)
[000175] Other embodiments of the invention include, among others, the following couplings for extending the half-life: HSA-binding lipid or small molecule or micelle for the monomeric or dimeric version of the fusion.
[000176] In certain embodiments of the invention, other couplings can be made to proteins, polypeptides and / or peptides of the invention, in order to achieve an extended half-life and for other improved biological properties. These may include attaching PEG-cholesterol conjugates (including micelles and liposomes) to proteins, polypeptides and / or peptides of the invention, and / or attaching sugars (glycosylates) to the proteins, polypeptides and / or peptides of the invention. In yet other embodiments, similar techniques are employed to add conjugates of, for example, polyisalic acid (PSA), hydroxyethyl starch (HES), albumin-binding ligands or carbohydrates as a shield to proteins, polypeptides and / or peptides .
[000177] The HESylation technique, for example, couples hydroxyethyl starch (HES) chains (60 kDa or 100 kDa, highly reamified corn starch-derived amylopectin fragments) to a protein, polypeptides and / or peptides via alkylation reductive. Polysialation conjugates proteins, polypeptides and / or peptides of interest with polymers of polysilic acid (PSA) in a similar way to PEGylation. PSA polymers are non-immunogenic, negatively charged polymers that occur naturally in the body and are available in molecular weights of 10-50 kD.
[000178] In yet other embodiments of the invention, other bonds or modifications can be made to proteins, polypeptides and / or peptides of the invention to achieve extended half-life and other improved biological properties. These include the creation of recombinant PEG groups (rPEG) and their attachment to the proteins, polypeptides and / or peptides of the invention. As developed by Amunix, Inc., rPEG technology is based on protein sequences with properties similar to PEG that are genetically fused to biopharmaceutical substances, avoiding the extra step of chemical conjugation. rPEGs are extended length half-life constructs and contain a long tail that does not contain hydrophilic amino acids and that are capable of increasing the serum half-life of a protein or peptide and slowing its absorption rate, thereby reducing significantly the peak-to-valley ratio. rPEGs have an increased hydrodynamic radius and show an apparent molar mass that is approximately 15 times that of its actual molar mass, mimicking the way in which PEGylation achieves a long serum half-life. Truncated FGF21 polypeptides
[000179] One embodiment of the present invention is directed to truncated forms of the mature FGF21 polypeptide (SEQ ID NO: 3). This embodiment of the present invention arose from an attempt to identify truncated FGF21 polypeptides that were capable of providing a similar and, in some cases, superior activity to the non-truncated forms of the mature FGF21 polypeptide.
[000180] In this specification, the term "truncated FGF21 polypeptide" refers to a FGF21 polypeptide in which the amino acid residues have been removed from the amino-terminal (or N-terminal) end of the FGF21 polypeptide, amino acid residues have been removed from the carboxyl-terminal (or C-terminal) end of the FGF21 polypeptide or amino acid residues were removed at the amino-terminal and carboxyl-terminal ends of the FGF21 polypeptide. The various truncations described herein have been prepared according to the description in this patent application.
[000181] It is possible to evaluate the activity of N-terminal truncated FGF21 polypeptides and of C-terminal truncated FGF21 polypeptides using an in vitro phospho-ERK assay. Specific details of the in vitro assays that can be used to examine the activity of truncated FGF21 polypeptides can be found in the examples.
[000182] The activity of the truncated FGF21 polypeptides of the present invention can also be evaluated in an in vivo assay, such as in ob / ob mice. In general, to assess its activity in vivo, the truncated FGF21 polypeptide is administered to a test animal intraperitoneally. After a desired incubation period (for example, an hour or more), a blood sample can be collected, and blood glucose levels can be measured. N-terminal truncations
[000183] In some embodiments of the present invention, the N-terminal truncations comprise 1,2,3, 4, 5, 6, 7 or 8 amino acid residues from the N-terminal end of the mature FGF21 polypeptide. Truncated FGF21 polypeptides having truncations of less than 9 amino acid residues retain the ability of the mature FGF21 polypeptide to decrease blood glucose in an individual. Thus, in specific embodiments, the present invention encompasses truncated forms of the mature FGF21 polypeptide or protein variants of FGF21 having truncations at the N-terminus of 1, 2, 3, 4, 5, 6, 7 or 8 amino acid residues. B. C-Terminal truncations
[000184] In some embodiments of the present invention, the C-terminal truncations comprise 1,2,3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues of the C-terminal end of the polypeptide - mature FGF21 deo. FGF21 polypeptides truncated with truncations at the C-terminal that were less than 13 amino acid residues exhibited an efficacy of at least 50% that of wild-type FGF21 in an in vitro ELK-luciferase assay (Yie J. et al., FEBS Letts 583: 19-24 (2009)), indicating that these FGF21 mutants retain the ability of the mature FGF21 polypeptide to reduce blood glucose in an individual. Thus, in specific embodiments, the present invention encompasses truncated forms of the mature FGF21 polypeptide or protein variants of FGF21 with truncations at the C-terminal of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. ç. N-terminal and C-terminal truncations
[000185] In some embodiments of the present invention, truncated FGF21 polypeptides may have a combination of N-terminal and C-terminal truncations. The truncated FGF21 polypeptides that exhibit combined N-terminal and C-terminal truncations share the activity of the corresponding truncated FGF21 polypeptides that exhibit truncations only at the N-terminal or C-terminal. In other words, truncated FGF21 polypeptides having N-terminal truncations less than 9 amino acid residues and C-terminal truncations less than 13 13 amino acid residues have similar or greater blood glucose lowering activity than truncated FGF21 polypeptides having truncations at the N-terminal less than 9 residues or that truncated FGF21 polypeptides having truncations at the C-terminal less than 13 amino acid residues. Thus, in specific embodiments, the present invention encompasses truncated forms of the mature FGF21 polypeptide or protein variants of FGF21 having truncations at the N-terminus of 1, 2, 3, 4, 5, 6, 7 or 8 amino acid residues and C-terminal truncations of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues.
[000186] As with all FGF21 variants of the present invention, the truncated FGF21 polypeptides can optionally comprise a methionine residue at the amino terminus, which can be introduced by direct mutation or as a result of a bacterial expression process.
[000187] The truncated FGF21 polypeptides of the present invention can be prepared as described in the examples presented below. Those skilled in the art, familiar with standard molecular biology techniques, can employ this knowledge, coupled with this invention, to produce and use the truncated FGF21 polypeptides of the present invention. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, tissue culture and transformation (eg, electroporation, lipofection). See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, supra, the content of which is incorporated herein by reference in this patent application for any purpose. Enzymatic reactions and purification techniques can be performed according to the manufacturers' specifications, as commonly performed in the technique or as described here. Unless specific definitions are provided, the nomenclatures used in connection, in addition to the laboratory procedures and techniques of analytical chemistry, synthetic organic chemistry and medicinal and pharmaceutical chemistry, described in this patent application, are those well known and commonly used in the art . Standard techniques can be used for chemical syntheses, chemical analyzes, for pharmaceutical preparation, formulation and release and treatment of patients.
[000188] The truncated FGF21 polypeptides of the present invention can also be fused to another entity, which can impart additional properties to the truncated FGF21 polypeptide. In one embodiment of the present invention, a truncated FGF21 polypeptide can be fused to an IgG constant domain or its fragment (e.g., the Fc region), to human serum albumin (HSA) or to albumin-binding polypeptides. Such a fusion can be accomplished using known methods of molecular biology and / or the guidance provided in this specification. The benefits of such fusion polypeptides, as well as methods for producing such fusion polypeptides, are discussed in more detail below. FGF21 fusion proteins
[000189] In this specification, the term "FGF21 fusion polypeptide" or "FGF21 fusion protein" refers to a fusion of one or more amino acid residues (such as a heterologous protein or peptide) at the N-terminus or at the C-terminus of any protein variant of FGF21 described in this patent application.
[000190] FGF21 fusion proteins can be produced by fusing heterologous sequences at the N-terminus or at the C-terminus of, for example, a variant of the FGF21 protein, as defined herein. In this specification, a heterologous sequence can be an amino acid sequence or a polymer containing no amino acids. The heterologous sequences can be fused directly to the FGF21 protein variant or via a linker or an adapter molecule. A linker or adapter molecule can be one or more amino acid residues (or isomers), for example, 1, 2, 3, 4, 5, 6, 7, 8 or 9 residues (or isomers), preferably from 10 to 50 amino acid residues (or ions), for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45 or 50 residues (or ions) ), and more preferably from 15 to 35 amino acid residues (or dimers). An adapter ligand or molecule can also be designed with a cleavage site for a DNA restriction endonuclease or protease and allow the fused groups to separate.
[000191] Heterologous peptides and polypeptides include, among others, an epitope to allow the detection and / or isolation of a FGF21 protein variant; a transmembrane receptor protein or a part thereof, such as an extracellular domain or a transmembrane and intracellular domain; a linker or part thereof that binds to a transmembrane receptor protein; an enzyme or part thereof with catalytic activity; a polypeptide or peptide that promotes oligomerization, such as a leucine zipper domain; a polypeptide or peptide that increases stability, such as an immunoglobulin constant region; a functional or non-functional antibody or one of its heavy or light chains; and a polypeptide that has an activity, such as a therapeutic activity, different from the variants of the FGF21 protein of the present invention. The present invention also encompasses FGF21 mutants fused to human serum albumin (HSA). Fc fusions
[000192] In one embodiment of the present invention, a variant of the FGF21 protein is fused to one or more domains of a human IgG Fc region. The antibodies comprise two functionally independent parts, a variable domain known as "Fab", which binds an antigen, and a constant domain known as "Fc", which is involved in effector functions such as complement activation and attack by phagocytic cells. An Fc has a long serum half-life, whereas a Fab is short-lived (Capon et al., 1989, Nature 337: 525-31). When coupled to a therapeutic protein, an Fc domain can extend half-life or incorporate such functions as binding to the Fc receptor, binding to protein A, complement fixation and perhaps even placental transfer (Capon et al., 1989).
[000193] Throughout this specification, Fc-FGF21 refers to a fusion protein in which the Fc sequence is fused to the N-terminus of FGF21. Likewise, throughout the specification, FGF21-Fc refers to a fusion protein in which the Fc sequence is fused to the C-terminus of FGF21.
[000194] Preferred embodiments of the invention are Fc-FGF21 fusion proteins that comprise variants of FGF21 as described herein. Especially preferred embodiments are Fc-FGF21 fusion proteins that comprise a modified Fc fragment (e.g., FcLALA) and variants of FGF21 as described herein.
[000195] The fusion protein can be purified, for example, by using an affinity column for protein A. Peptides and proteins fused to an Fc region have been shown to exhibit a significantly longer half-life in vivo than non-fused counterparts. In addition, a fusion to an Fc region allows dimerization / multimerization of the fusion polypeptide. The Fc region can be a naturally occurring Fc region or can be altered to improve certain qualities, such as therapeutic qualities, circulation time or reduced aggregation.
[000196] Useful modifications of protein therapeutic agents by fusion with the "Fc" domain of an antibody are discussed in detail in PCT Publication No. WO 00/024782.
[000197] This document discusses the connection to a "vehicle" such as polyethylene glycol (PEG), dextran or an Fc region. B. Fusion protein binders
[000198] In forming the fusion proteins of the present invention, a linker can, but need not be, employed. When present, the chemical structure of the binder may not be critical, since it serves primarily as a spacer. The linker can consist of amino acids joined by peptide bonds. In some embodiments of the present invention, the linker consists of 1 to 20 amino acids joined by peptide bonds, where the amino acids are selected from the 20 naturally occurring amino acids. In various embodiments, 1 to 20 amino acids are selected from the amino acids glycine, serine, alanine, proline, asparagine, glutamine and lysine. In some embodiments, a linker consists of, for the most part, amino acids without stereochemical impediment, such as glycine and alanine. In some embodiments, the binders are polyglycines, polyalanines, combinations of glycine and alanine (such as poly (Gly-Ala)) or combinations of glycine and serine (such as poly (Gly-Ser)). Although a linker of 15 amino acid residues has been found to work especially well for FGF21 fusion proteins, the present invention contemplates linkers of any length or composition.
[000199] The binders described herein are exemplary, and much longer binders and which include other residues are contemplated by the present invention. Non-peptide linkers are also contemplated by the present invention. For example, alkyl-formed binders can be used. These alkyl binders can be further substituted with a group without stereochemical impediment, including, among others, lower alkyl (for example, C1-C6), lower acyl, halogen (for example, CI, Br), CN, NH2 or phenyl. An exemplary non-peptide linker is a polyethylene glycol linker, wherein the linker has a molecular weight of 100 to 5000 kD, for example, 100 to 500 kD. Chemically modified fusion proteins
[000200] Chemically modified forms of the fusion proteins described herein, including, for example, truncated forms and variants of the FGF21 fusions described herein, can be prepared by the person skilled in the art, given the descriptions contained herein. Such chemically modified fusion proteins are altered in such a way that the chemically modified mutant is different from the unmodified mutant, either in the type or location of molecules naturally bound to the mutant. Chemically modified mutants can include molecules formed by the deletion of one or more naturally bound chemical groups.
[000201] In one embodiment, proteins of the present invention can be modified by covalently bonding one or more polymers. For example, the selected polymer is typically water-soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Within the scope of suitable polymers, a mixture of polymers is included. Preferably, for therapeutic use of the final product preparation, the polymer will be pharmaceutically acceptable. Non-water-soluble polymers conjugated to proteins of the present invention also form an aspect of the invention.
[000202] Exemplary polymers can each be of any molecular weight and can be branched or not. Polymers typically have an individual average molecular weight between approximately 2 kDa and approximately 100 kDa (the term "approximately" indicating that in preparations of a water-soluble polymer, some molecules will weigh more and others less than the declared molecular weight). The average molecular weight of each polymer is preferably between approximately 5 kDa and approximately 50 kDa, more preferably between approximately 12 kDa and approximately 40 kDa and, most preferably, between approximately 20 kDa and approximately 35 kDa.
[000203] Suitable water-soluble polymers or mixtures thereof include, but are not limited to, N-linked or O-linked carbohydrates, sugars, phosphates, polyethylene glycol (PEG) (including forms of PEG that have been used for protein derivation, including mono - (C1-C10), alkoxy, or aryloxy-polyethylene glycol), monomethoxy-polyethylene glycol, dextran (such as low molecular weight dextran of, for example, approximately 6 kD), cellulose or other polymers based on carbohydrates , poly- (N-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethoxylated polyols (eg glycerol) and polyvinyl alcohol. The present invention also encompasses bifunctional cross-linking molecules that can be used to prepare multimers of covalently linked FGF21 protein variants. The present invention also encompasses FGF21 mutants covalently linked to polysalic acid.
[000204] Polysaccharide polymers represent another type of water-soluble polymer that can be used for protein modification. Therefore, the fusion proteins of the invention fused to a polysaccharide polymer form embodiments of the present invention. Dextrans are polysaccharide polymers that comprise individual glucose subunits predominantly linked by alpha-1-6 bonds. Dextran itself is available in many molecular weight ranges and is readily available in molecular weights from approximately 1 kD to approximately 70 kD. Dextran is a suitable water-soluble polymer for use as a vehicle by itself or in combination with another vehicle (eg, Fc). See, for example, International Publication No. WO 96/11953. The use of dextran in conjunction with therapeutic or diagnostic immunoglobulins has been reported. See, for example, European Patent Publication No. 0 315 456, the content of which is incorporated herein by reference in this patent application. The present invention also encompasses the use of dextran from approximately 1 kD to approximately 20 kD.
[000205] In general, chemical modification can be carried out under any suitable condition used to react a protein with an activated polymeric molecule. Methods for preparing chemically modified polypeptides will generally comprise the steps of: (a) reacting the polypeptide with the activated polymer molecule (such as a reactive ester or aldehyde derivative of the polymer molecule) under conditions by which a variant of the FGF21 protein makes it bound to one or more molecules of the polymer and (b) obtaining the reaction products. The ideal reaction conditions will be determined based on known parameters and the desired result. For example, the higher the ratio of molecules from polymer to protein, the higher the percentage of polymer molecule bound. In one embodiment of the present invention, chemically modified FGF21 mutants may have a single polymeric molecule at the amino terminus (see, for example, U.S. Patent No. 5,234,784).
[000206] In another embodiment of the present invention, proteins of the invention can be chemically coupled to biotin. The proteins / biotin of the invention are then left to bind to avidin, resulting in avidin / biotin / tetravalent proteins of the invention. Proteins of the invention can also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugates precipitated with anti-DNP or anti-TNP IgM to form decameric conjugates with a valency of 10.
[000207] In general, conditions that can be alleviated or modulated by administering the chemically modified mutant FGF21 of the present invention include those described herein for proteins of the invention. However, the chemically modified FGF21 mutants disclosed herein may have additional activities, enhanced or reduced biological activity or other characteristics, such as increased or decreased half-life, when compared to unmodified FGF21 mutants. Therapeutic compositions of fusion proteins and their administration
[000208] The present invention also provides therapeutic compositions comprising one or more of the fusion proteins of the invention, described herein, and in admixture with a pharmaceutically or physiologically acceptable formulation agent or with a pharmaceutically acceptable carrier selected for suitability. with the mode of administration. The compositions are specifically contemplated in the light of, for example, the identification of fusion proteins exhibiting enhanced properties.
[000209] In some embodiments, therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution or suspension in liquid vehicles before injection can also be prepared. Limits are included within the definition of a pharmaceutically acceptable vehicle. Pharmaceutically acceptable salts can also be present in the pharmaceutical composition, for example, mineral salts of acids such as hydrochlorides, hydrobromides, phosphates, sulfates and the like; and salts of organic acids such as acetates, propionates, malonates, benzoates and the like. An in-depth discussion of pharmaceutically acceptable excipients is available in Remington: The Science and Practice of Pharmacy (1995) Alfonso Gennaro, Lippincott, Williams, & Wilkins.
[000210] Acceptable formulation materials are preferably non-toxic to the recipients at the doses and concentrations employed.
[000211] The pharmaceutical composition can contain formulation materials to modify, maintain or preserve, for example, pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate dissolution or release, adsorption or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfide or sodium hydrogen sulfide), buffers (such as borate, bicarbonate, Tris-HCI, citrates, phosphates or other organic acids), massing agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetracetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides and other carbohydrates (such as glucose, mannose or dextrins), proteins (such as serum albumin, gelatin or immunoglobulins), coloring agents, flavoring and diluents, emulsifying agents , hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzo acid ico, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide), solvents (such as glycerin, propylene glycol or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfac- substances or moisturizing agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tiloxapal), stability-enhancing agents (such as sucrose or sorbitol), tonicity-reinforcing agents (such as alkali metal halides; preferably sodium or potassium chloride; or mannitol sorbitol), delivery vehicles, diluents, excipients and / or pharmaceutical adjuvants (see, for example, Remington's Pharmaceutical Sciences (18aed., AR Gennaro, ed., Mack Publishing Company 1990) and its subsequent editions, incorporated herein by reference in this patent application for any purpose).
[000212] The ideal pharmaceutical composition will be determined by the person skilled in the art depending, for example, on the intended route of administration, the release format and the desired dose (see, for example, Remington's Pharmaceutical Sciences, supra). Such compositions can influence the physical state, stability, the rate of in vivo release and the rate of in vivo clearance of the fusion protein of the invention.
[000213] The primary vehicle or carrier in a pharmaceutical composition can be of an aqueous or non-aqueous nature. For example, a suitable vehicle or carrier for injection may be water, physiological saline or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are still exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer with a pH of approximately 7.0-8.5, or acetate buffer with a pH of approximately 4.0-5.5, which may further include sorbitol or a suitable substitute. In an embodiment of the present invention, dual-function pharmaceutical compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (Remington's Pharmaceutical Sciences, supra) in the form of lyophilized cake or solution watery. In addition, the dual function protein product can be formulated into lyophilisate using appropriate excipients such as sucrose.
[000214] Pharmaceutical compositions containing the fusion proteins of the invention can be selected for parenteral release. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.
[000215] The components of the formulation are present in concentrations that are acceptable for the site of administration. For example, buffers are used to maintain the composition at a physiological pH or at a slightly lower pH, typically within a pH range between approximately 5 and approximately 8.
[000216] When parenteral administration is contemplated, the therapeutic compositions for use in this invention may be in the form of a pyrogen-free aqueous solution, acceptable for parenteral route, comprising the desired dual function protein in a pharmaceutically acceptable carrier. An especially suitable vehicle for parenteral injection is sterile distilled water in which a dual-function protein is formulated as a sterile, properly preserved isotonic solution. Yet another preparation may involve the formulation of the desired molecule with an agent, such as injectable microspheres, bioerosible particles, polymeric compounds (such as polyisolic acid or polyglycolic acid), microspheres or liposomes, which provide the controlled or sustained release of the product that can then be released through a deposit injection. Hyaluronic acid can also be used and this can have the effect of promoting sustained duration in the circulation. Another suitable means for introducing the desired molecule includes implantable drug delivery devices.
[000217] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a dual-function protein of the invention can be formulated as a dry powder for inhalation. Solutions containing the dual function protein for inhalation can be formulated with an aerosol release propellant. In yet another embodiment, the solutions can be nebulized. Pulmonary administration is described in more detail in International Publication No. WO 94/20069, which describes the pulmonary release of chemically modified proteins.
[000218] It is also contemplated that certain formulations can be administered orally. In one embodiment of the present invention, fusion proteins of the invention that are administered in this manner can be formulated with or without those carriers commonly used in the composition of solid dosage forms such as tablets or capsules. For example, a capsule can be created to release the active part of the formulation at the point of the gastrointestinal tract when bioavailability is at a maximum and pre-system degradation is at a minimum. Additional agents can be included to facilitate the absorption of the inventive fusion proteins. Diluents, flavorings, low melting waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents and binders can also be used.
[000219] Another pharmaceutical composition may involve an effective amount of the fusion proteins of the invention in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. Dissolving the tablets in sterile water, or another suitable vehicle, allows solutions to be prepared as a unit dose. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose or calcium phosphate; or binding agents, such as starch, gelatin or acacia; or lubricating agents such as magnesium stearate, stearic acid or talc.
[000220] Additional pharmaceutical compositions comprising fusion proteins of the invention will be apparent to those skilled in the art, including formulations involving fusion proteins of the invention in formulations for sustained or controlled release. Techniques for formulating a variety of other means for sustained or controlled delivery, such as liposomal carriers, bioerosible microparticles or porous microspheres and deposit injections, are also known to those skilled in the art (see, for example, International Publication No. WO 93 / 15722, which describes the controlled release of porous polymeric microparticles for the release of pharmaceutical compositions, in addition to Wischke & Schwendeman, 2008, Int. J Pharm. 364: 298-327 and Freiberg & Zhu, 2004, Int. J Pharm. 282: 1-18, which discuss the preparation and use of microspheres / microparticles).
[000221] Additional examples of sustained release preparations include semipermeable polymeric matrices in the form of molded items, for example, films or microcapsules. Sustained-release matrices may include polyesters, hydrogels, polylactides (US Patent No. 3,773,919 and European Patent No. 0 058 481), copolymers of L-glutamic acid and ethyl-L-glutamate range (Sidman et al., 1983, Biopolymers 22: 547-56), poly (2-hydroxyethyl-methacrylate) (Langer et al., 1981, J. Biomed. Mater. Res. 15: 167-277 and Langer, 1982, Chem. Tech. 12: 98- 105), vinyl ethylene acetate (Langer et al., Supra) or poly-D-3-hydroxybutyric acid (European Patent No. 0 133 988). Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art. See, for example, Epstein et al., 1985, Proc. Natl. Acad. Sci. USA, 82: 3688-92; and European Patents Nos. 0 036 676, 0 088 046 and 0 143 949.
[000222] The pharmaceutical compositions of the invention to be used for in vivo administration typically need to be sterile. This can be accomplished by passing through sterile filtration membranes. When the composition is lyophilized, sterilization using this method can be conducted before or after lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions are generally placed in a container with a sterile access port, for example, a bag of intravenous solution or vial with a stopper that can be punctured by a hypodermic injection needle.
[000223] Once it has been formulated, the pharmaceutical composition can be stored in sterile vials in a solution, suspension, gel, emulsion, solid or in the form of dehydrated or lyophilized powder. Such formulations can be stored in a form for immediate use or in a form (for example, lyophilized) that requires reconstitution before administration.
[000224] In a specific embodiment, the present invention is directed to kits for producing a single dose unit for administration. The kits can each contain a first container having a dry protein and a second container having an aqueous formulation. The scope of this invention also includes kits containing pre-filled syringes with a single compartment or multiple compartments (for example, syringes containing liquids and syringes containing lyophilisate). Doses of fusion proteins and their administration
[000225] The effective amount of a pharmaceutical composition of the invention to be employed therapeutically will depend, for example, on the therapeutic context and objectives. The person skilled in the art will recognize that adequate dose levels for treatment will therefore vary, depending in part on the derived molecule, the indication for which the variant of the fusion protein is being used, the route of administration and the size (weight body size, body surface, or organ size) and the condition (age and general health) of the patient. Thus, the clinician can titrate the dose and modify the route of administration to obtain the ideal therapeutic effect. A typical dose can range from approximately 0.1 μg / kg to approximately 100 mg / kg or more, depending on the factors mentioned above. In other embodiments, the dose can vary from 0.1 μg / kg to approximately 100 mg / kg; or from 1 μg / kg to approximately 100 mg / kg.
[000226] The frequency of administration will depend on the pharmacokinetic parameters of the dual function protein in the formulation in use. Typically, a clinician will administer the composition until a dose is reached that achieves the desired effect. The composition can therefore be administered in a single dose, in two or more doses (which may or may not contain the same amount of the desired molecule) over time or as a continuous infusion through an implanted device or catheter. Further refinement of the appropriate dose is carried out routinely by those skilled in the art and is within the scope of routine tasks. Appropriate doses can be ascertained using appropriate dose-response data.
[000227] The route of administration of the pharmaceutical composition is in accordance with known methods, for example, orally; through intravenous, intraperitoneal, intracerebral (intraparenchymatous), intracerebroventricular, intramuscular, intraarterial, intraportal or intralesional injection; by sustained release systems (which can also be injected); or by implanted devices. When desired, the compositions can be administered by bolus injection, continuously by infusion or by implanted device.
[000228] Alternatively or in addition, the composition can be administered locally via implantation of a membrane, sponge or other appropriate material in which the desired molecule has been absorbed or encapsulated. When an implanted device is used, it can be implanted in any suitable tissue or organ, and the release of the desired molecule can be through diffusion, timed release boluses or continuous administration. Therapeutic uses of fusion proteins
[000229] The proteins of the invention can be used to treat, diagnose, alleviate or prevent a variety of diseases, disorders or conditions, including, among others, metabolic disorders. In one embodiment, the metabolic disorder to be treated is diabetes, for example, type 2 diabetes mellitus. In another embodiment, the metabolic disorder is obesity. Other embodiments include metabolic conditions or disorders such as type 1 diabetes mellitus, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, syndrome metabolic, hypertension, cardiovascular disease, acute myocardial infarction, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, kidney disease, diabetic complications, neuropathy, disorders associated with severe inactivating mutations in the insulin receptor, gastroparesis and other metabolic disorders.
[000230] In the application, a disorder or condition such as type 1 or type 2 diabetes or obesity can be treated by administering a variant of the FGF21 protein as described herein to a patient in need of such treatment in the amount of a therapeutically effective dose . Administration can be performed as described herein, such as by IV injection, intraperitoneal injection, intramuscular injection or orally in the form of a tablet or liquid formation. In most situations, a desired dose can be determined by a clinician, as described herein, and can represent a therapeutically effective dose of the mutant FGF21 polypeptide. It will be apparent to those skilled in the art that a therapeutically effective dose of the mutant FGF21 polypeptide will depend, among others, on the administration schedule, the unit dose of antigen administered, whether the nucleic acid or polypeptide molecule is administered with others therapeutic agents, the immune situation and the health of the recipient. The term "therapeutically effective dose" in this specification means that amount of FGF21 mutant polypeptide that elicits the biological or medicinal response in a tissue, animal or human system, that a researcher, doctor or other clinician is looking for, and that include relieving symptoms of the disease or disorder being treated.
[000231] Having now been described in detail, the present invention will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and not to limit the invention.
[000232] The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are fully explained in the literature. See, for example, Remington's Pharmaceutical Sciences, 18th edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.); and Handbook of Experimental Immunology, Vol. I-IV (D.M. Weir and C.C. Blackwell, eds., 1986, Blackwell Scientific Publications); and Sam- brook et al., Molecular Cloning: A Laboratory Manual (2nd edition, 1989). Examples Example 1: Preparation of FGF21 variant proteins
[000233] Construction for FGF21 V76 expression: FGF21 variants were cloned into the modified E.coli pET30a expression vector, described by Achmuller et al. (2007) (Nature Methods4: 10371043), to generate in-frame fusions to a hexa-histidine tag followed by the Npro-EDDIE tag at the N-terminal of FGF21 (aa 33-209).
[000234] FGF21 V76 expression and purification: The expression plasmid pET30a-His-Npro-EDDIE-FGF21 was transformed into competent E. coli BL21 Star (DE3) cells (Invitrogen). Overnight growth of a single colony of recently transformed cells was performed in 50 mL of Terrific Broth (TB) containing 50 μg / mL canamycin at 37 ° C. The pre-culture was transferred to 1 L of TB medium with kanamycin and grown in flasks with deep recesses at 37 ° C with agitation at 250 rpm. After 6 hours of culture, FGF21 expression was induced by adding IPTG to a final concentration of 1 mM, and the cultures were grown overnight at 37 ° C. The cells were then harvested and resuspended in 50 ml of cold lysis buffer; 50 mM Tris-HCI, pH 8, 150 mM NaCI, 1 mM EDTA, followed by the smooth using a Microfluidizer ™.
[000235] Inclusion bodies (IBs) were precipitated by centrifugation at 30,000 x g for 1 hour at 4 ° C. The IBs were washed with 50 mM Tris-HCI, pH 8, 150 mM NaCI and then dissolved in 30 ml of dissolution buffer; 10 mM Tris-HCI, pH 8, 100 mM NaH2P04, 6 M GnHCI. The dissolved IBs were clarified by centrifugation at 30,000 x g for 1 hour at 25 ° C. The IB solution was loaded onto a column of 5 mL of high efficiency Ni-NTA resin (GE Healthcare) equilibrated with dissolution buffer. Proteins bound to the resin were eluted lowering the pH to 4.5. The eluate was conditioned by adjusting the pH and adding dithiothreitol (DTT) to a concentration of 20 mM. The conditioned eluate was slowly diluted to 1 L of refolding buffer; 50 mM Tris-HCI, pH 8, 0.5 M arginine, 20 mM DTT, followed by incubation for 2 days at 4 ° C. The diluted sample was concentrated and the buffer exchanged for 20 mM Tris-HCI, pH 9 using an ultrafiltration method. The concentrated sample was loaded onto a 10 mL column of Q flow fast Q sepharose resin (GE Healthcare) equilibrated with 20 mM Tri-HCI (pH 9).
[000236] After washing the resin with the equilibration buffer, the proteins bound to the resin were eluted with 20 mM Tris-HCl, pH 9, 500 mM NaCI. To remove the His-Nprocleaved fusion fragment and any uncleaved fusion protein from the FGF21 protein again folded, the eluate was loaded onto a 5 ml column of high-efficiency Ni-NTA resin balanced with 20 mM Tris, pH 8, 0, 50 mM imidazole, and the fraction through the flow containing FGF21 was collected. To reduce endotoxin levels, the FGF21 fraction was treated with an EndoTrap HD resin (Hyglos) balanced with 10 mM Tris, pH 8, 50 mM imidazole, 500 mM NaCI, 1 mM CaCI2. The low endotoxin sample was dialyzed against PBS and then sterilized with a 0.22 μm filter. The purified FGF21 protein was instantly frozen in liquid nitrogen and stored at -80 ° C. The protein concentration was determined by absorbance at 280 nm using 9362 M-1 cm-1 as the molar extinction coefficient for FGF21. Protein purity and integrity were determined by HPLC, SDS-PAGE and liquid chromatography-mass spectrometry.
[000237] FGF21 cysteine pegylation variants: FGF21 V75 variant (R154C) tends to dimerize via the constructed cysteine; therefore, prior to PEGylation, the protein-containing solution (typically 5 mg / mL in Tris buffer) was gently reduced with 5 mM mercaptoethylamine for 30 minutes on ice and immediately desalted in 20 mM Tris, pH 7. The recently reduced protein (typically 3 mg / ml) was then immediately PEGylated with 1.5 equivalents of the 40 kDa branched maleimido-PEG reagent (NOF, Cat. In the GL2-400MA of the Sunbright series) for 3 hours on ice. The PEGylated protein was finally purified by anion exchange chromatography (MonoQ) with overall yields of approximately 25%.
[000238] Constructions for Expression of Fc-FGF21 Fusion Variants: FGF21 variant cDNAs encoding amino acids 33-209 were cloned into a mammalian expression vector downstream of the cytomegalovirus (CMV) promoter in frame with N-terminal sequences including a leader peptide (immunoglobulin kappa chain) to direct protein secretion, followed by an Fc domain and a short ligand.
[000239] Expression and purification of Fc-FGF21 variants: The Fc-FGF21 variant proteins were expressed in HEK293T cells (American Type Culture Collection). The cells were cultured in suspension by 37 ° C, 8% CO2, in Freestyle Expression Medium 293 (Invitrogen, Cat. No 12338-018) until the day of transfection. The cells were centrifuged at 1000 x g for 7 minutes in a horizontal rotor and counted with an automatic cell counter. The cells were diluted in 900 ml of Freestyle 293 medium to a final concentration of 1.4 x 10 6 cells / ml and placed in a flask without recess in the 3 L bottom (Corning, Cat. No 431252). The cells were transfected using a mixture of polyethyleneimine (PEI) and plasmid as follows: three mL of a sterile stock at 1 mg / mL of linear PEI, MW 25,000, (Alfa Aesar, Cat. No 43896) were added at 50 mL of Freestyle 293 medium, mixed gently and incubated at 25 ° C for 5 minutes. At the same time, 1 mg of endotoxin-free plasmid was added to 50 ml of Freestyle 293 medium and filtered sterile using a 0.2 μM filter. The PEI mixture was then added to the sterile filtered DNA, mixed gently and allowed to incubate at 25 ° C for 10 minutes. The PEI-plasmid mixture was then added to the 3 L flask containing the diluted HEK 293T cells and placed in an incubator shaken at 125 RPM, 37 ° C, 8% CO2.
[000240] On the 6th day after transfection, the cells were centrifuged at 2000 x g for 10 minutes and the supernatant was harvested. The supernatant was further clarified by filtration through a 0.8 / 0.2 μM filter (Pall Corporation, Cat. No 4628).
[000241] The batch purification of FGF21 protein was carried out by the addition of 1 mL of Sepharose Fast Flow of recombinant Protein A (GE, Cat. No. 17-5138-03) per 20 mg of protein expected to be purified, directly for the clarified supernatant, and incubation for 1 hour at 4 ° C with gentle rotation. The supernatant mixture was then poured onto a disposable Poly-Prep chromatography column (Bio-Rad, Cat. No. 731-1550), and the flow through was discarded. The retained microspheres were washed with 5 column volumes of DPBS, pH 7.4 (Invitrogen, Cat. No 14190-144). Protein elution from protein A microspheres was performed by adding 20 column volumes of sodium citrate buffer, pH 3.0. The elution buffer was neutralized by the addition of 20% Tris-HCl buffer, pH 9.0. Size exclusion chromatography was performed as a secondary polishing step by running the purified material in a batch of protein A in a High Load 26/600 Superdex 200pg column (GE, Cat. No 289893-36). The yield of purified protein was quantified by A280. A run of SDS-Page was carried out to check the purity and molecular weight. The level of endotoxins was quantified using the Endosafe PTS system (Charles River Labs). Example 2: FGF21-dependent measurement of 2-deoxyglucose uptake (2-DOG)
[000242] FGF21 has been shown to stimulate glucose uptake in 3T3-L1 adipocytes from mice in the presence and absence of insulin, and to increase blood levels of glucose, triglycerides and glucagon in the fed and fasted state in ob / ob and db / db mice and 8 week old ZDF rats in a dose dependent manner, thus providing the basis for the use of FGF21 as a therapy to treat diabetes and obesity (see, for example, Patent Publication WO03 / 011213, and Kharitonenkov et al ., (2005) Jour. Of Clinical Invest. 115: 1627-1635). Additionally, it was observed that FGF21 stimulated tyrosine phosphorylation of FGFR-1 and FGFR-2 in 3T3-L1 adipocytes.
[000243] 3T3-L1 fibroblasts were purchased from ATCC (Cat. No CL173). The cells were cultured to confluence in a 150 cm Petri dish and kept in DMEM with high glucose content (Invitrogen, Cat. No. 11995065) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for 4 more days . The cells were then differentiated into the above medium supplemented with insulin 4 μg / mL (Sigma, Cat. No I-5500), IBMX 115 μg / mL (Sigma, Cat. No I5879) and dexamethasone 0.0975 μg / mL ( Sigma, Cat. No D1756) for 3 days after which the differentiation medium was replaced with complete DMEM. A differentiated 3T3-L1 adipocyte plate was seeded in four 96-well plates the day after the medium was replaced.
[000244] The adipocytes were then treated with FGF21-WT and the FGF21 variant protein (see Table 2 for the list of variants; 30 pM to 100 nM is the typical concentration range used) overnight in complete medium. The adipocytes treated with FGF21 samples were deprived of serum in 50 μL per well of KRH buffer (NaCI 0.75%; KCI 0.038%; CaCI2 0.0196%; MgS04 0.032%; HEPES 0.025 M, pH 7.5; BSA 0.5%; 2 mM sodium pyruvate) for 2 hours. The wells for the blank were added with 1 μL (final concentration: 5 μg / ml) of cythalhalin B for 15 minutes. [3H] -2-DOG (20.6 mCi / mmoL, 1 mCi / mL) was diluted 1:20 in cold 5.1 mM 2-DOG and 1 μL of diluted 2-DOG was added per well, and cells were incubated for 5 minutes. The cells were washed three times with 100 μL / well KRH buffer. 1% SDS 40 μL / well was added to the cells that were agitated for at least 10 minutes. Scintillation liquid 200 μL / well was added and the plates were shaken overnight and read in a beta-plate reader. The values obtained from an entire column / row, which were treated with cytochalasin B, were averaged and subtracted from all other values. The data were analyzed using the GraphPad Prism software, the results of which are summarized in Table 2. The Fc-FGF21 V101, V103 and V188 fusion variants are superior to the PEGylated variant V76 of FGF21 for inducing 2-deoxyglucose uptake by 3T3L1 adipocytes from mice . Example 3: pERK in Western cell assay (ICW)
[000245] HEK293 cells transfected stably with human β-klotho, grown in DMEM with high glucose content, 10% FBS, 1% PS and 600 ng / mL G418, are seeded in 96-well plates coated with poly-D-lysine (BD bioscience, Cat. No 356640) at 30,000 cells per well overnight. The cells were deprived of serum in DMEM with high glucose content, 0.5% BSA and 10 mM HEPES for 4 hours. FGF21 WT and FGF21 variants (see Table 3 for the list of variants) were diluted to various concentrations (100 pM to 300 nM is the typical concentration range used) in deprivation medium. The cells were stimulated with FGF21 for 10 minutes. After stimulation with FGF21 or the FGF21 variant protein, the medium was aspirated from the wells and the cells were washed once with 100 μL of cold PBS and then fixed with 100 μL of 4% formaldeldehyde for 15 minutes at room temperature and followed by an incubation for another 10 minutes with 100 μL of chilled methanol.
[000246] After fixation, the cells were washed four times with 0.3% Triton X-100 in PBS, 5 minutes each. 150 μL of Odyssey blocking buffer was added to the permeabilized cells at room temperature for 1.5 hours. The phospho-ERK antibody (pERK) was diluted to a concentration of 0.17 μg / mL (dilution 1: 200 or the dilutions indicated) and the ERK-total antibody (tERK) was diluted to a concentration of 2.2 μg / mL (1: 200 dilution or the dilutions indicated) in Odyssey blocking buffer. 50 μL was added to each well, omitting a column that was only treated with the secondary antibody to normalize the bottom. The plate was covered with the wet paper tower and the lid to prevent evaporation and then incubated at 4 ° C overnight.
[000247] After that period, the primary antibody was aspirated and the cells were washed four times with 0.3% Tween 20 in PBS for 5 minutes each. During the wash, the reaction mixture with the secondary antibody was prepared in Odyssey blocking buffer containing the diluted 1: 1000 goat anti-mouse Alexa 680 (or the dilutions indicated) and the diluted goat anti-rabbit IRDye800 1 : 1000 (or the dilutions indicated). Once washing was completed, 40 μL of the reaction mixture was added to each well. The plates were covered with a black cap to protect the secondary antibody from light, and were incubated at room temperature for 1 hour on a shaker. Finally, the cells were again washed four times with 0.3% Tween 20 in PBS for 5 minutes each, and then subjected to LI-COR Bioscience Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE) in the 700 nm (red) and 800 nm (green) channels. Alexa 680 stained the tERK with fluorescence in the distant red (emission wavelength: 668 nm), while IRDye800 stained the pERK with green fluorescence (emission wavelength: 800 nm). To eliminate the fluorescent background, the values obtained from an entire column / row that was treated with only the secondary antibody, were averaged and subtracted from all other values obtained from the plate. To normalize the amount of pERK present in each sample, the values for pERK in each well were divided by the values of tERK. The data were analyzed by the GraphPad Prism software, the results of which are summarized in Table 2. The Fc-FGF21 V101, V103 and V188 fusion variants are superior to the PEGylated V76 variant of FGF21 in this ERK phosphorylation assay. Table 2: Summary of ERK in Western cell assay results and glucose uptake by mice 3T3L1 adipocytes
Example 4: In vivo testing of FGF2 variants
[000248] The ob / ob mouse is a mouse model for type 2 diabetes. The mice lack functional leptin and are characterized by hyperglycemia, insulin resistance, hyperphagia, fatty liver and obesity. Male ob / ob mice (10-13 weeks old) were used to measure the effect on blood glucose of the PEGylated variant V76 of FGF21 and the following Fc-FGF21 fusion variants V101, V103 and V188.
[000249] Variants of FGF21 or the PBS vehicle were administered via SC at 1 mg / kg (V101, V103 and V188) or V76 via SC at 5 mg / kg twice a week for 12 days (4 doses in total ). On the first day of the study, tail blood glucose and body weight were measured, and the mice were distributed into different groups (n = 8 per group), in which the mean glucose and body weight were equal between the groups. Blood glucose was measured with a glucose meter (OneTouch). Plasma insulin was measured on Day 1 before administration and on Day 12, 24 hours after the last dose. The results of these studies are summarized in Table 5.
[000250] The results of these studies are summarized in Table 3 and Figures 1-3. The Fc-FGF21 V101, V103 and V188 fusion variants are superior to the PEGylated V76 variant of FGF21 at all times measured in these studies and at a dose five times lower. Table 3.% of changes compared to the vehicle in glucose and plasma insulin, body weight gain (BW), TG / lipids in the liver by FGF21 variants during 12-day studies in mice under ob / ob
Example 5: Pharmacokinetics of FGF21 fusion variants in mice
[000251] To determine the pharmacokinetic profile of the Fc-FGF21 fusion variants V101, V103 and V188, C57BL / 6J mice were injected IV with the test item 1 mg / kg and bled at various times of 16 days (384 hours ). Blood samples were collected in microtainer tubes coated with EDTA from the submandibular or retro-orbital plexus. Approximately 50 μL of blood was collected at each time, yielding ~ 25 μL of plasma.
[000252] To measure plasma concentrations of items under test by ELISA, 384-well plates were coated overnight at room temperature (RT) with 2 μg / mL of goat anti-human Fc-gamma polyclonal antibody (30 μL / well) and then blocked with casein-based diluent for 2 hours at RT (100 μL / well). Diluted samples, standards and controls were added to the plate (30 μL / well) and incubated for 2 hours at RT. After the samples were removed, the wells were washed three times with a phosphate-based washing solution (100 μL / well). The detection antibody, an HRP-tagged version of the capture antibody, was added to the plate and incubated for 1 hour at RT (30 μL / well). After the plate was rinsed again three times with a phosphate-based washing solution (100 μL / well), a chemiluminescent substrate was added (30 μL / well) and the luminescence of the plate was read within 5 minutes using a reader appropriate plate. As shown in Figures 4A and 4B, the Fc-FGF21 fusion variants showed a greatly increased half-life in relation to the Fc-FGF21 fusions known in the art (Figure 4A) and in relation to the PEGylated variant V76 of FGF21 (Figure 4B) .
[000253] The serum levels of the Fc-FGF21 test items were validated by the Western Blotting technique against levels measured by ELISA to ensure that the complete Fc-FGF21 variant and not only isolated Fc was being detected in the ELISA assay. Two μL of mouse serum were combined with 2.5 μL of 4X loading buffer, 1 μL of 10X denaturant and 4 μL of dH2O, heated to 95 ° C for 5 minutes and loaded on polyacrylate gel with gradient 4-12% and submitted to electrophoresis for 1 hour at 100 Volts (constant voltage). The samples were transferred to nitrocellulose filter paper by Western Blotting using the iblot system (Invitrogen, Cat. No IB1001, running time 7 minutes). The nitrocellulose filters were blocked with 30 mL of Rockland blocking solution (Cat. No MB-070), probed following the protocol of the snap iblot system with a primary goat anti-FGF21 antibody at a dilution of 1: 2000 (R&D systems , Cat. No BAF2539) and fluorescence-labeled strepavidin as secondary to a dilution of 1: 10,000 (Liquor, Cat. No 926-68031). The protein levels were visualized in the Licor Odyssey system at 700 nm and compared with the V101 control run at 2 nM on the same gel. As shown in Figure 4C, the complete V101, V103 and V188 variants of Fc-FGF21 are detectable using the Western Blotting technique with anti-FGF21 antibody from the 15-day mouse serum obtained from the pharmacokinetic study.
[000254] Example 6: Fusion variants Fc-FGF21 V101, V103 and V188 are extremely thermodynamically stable
[000255] Proteins can break down over a specific temperature range. Protein breakdown temperature is an intrinsic parameter to describe the thermal stability of proteins. Differential scanning calorimetry (DSC) is used to detect the protein's unfolding temperature. This characteristic temperature is described as the melting temperature (Tm), which is the peak temperature during protein unfolding.
[000256] Samples of original protein are diluted in PBS to a concentration of ~ 1 mg / ml (0.5 mg / ml to 1.2 mg / ml) to a total volume of 0.5 ml. A 0.4 mL aliquot per well of standard diluted protein sample, PBS and DI water is added to the 96-well DSC plate. The plate is then covered with a seal. The samples were analyzed in a MicroCal 96-well differential scanning calorimeter. The temperature was scanned at 10 - 110 degrees C at a rate of 1 degree per minute.
[000257] As shown in Figure 4D, the melting temperatures of FGF21 variants V101, V103 and V188 are extremely high. This data contrasts with the lower melting temperatures of the V76 variant of FGF21 and wild-type FGF21 (not shown). The improved stability of V101, V103 and V188 is attributed to the specific addition of a second disulfide bond resulting from the new mutations Q55C and G148C. This type of mechanical stability is known to protect proteins from proteolysis and can additionally translate into significantly prolonged stability in vivo and in the improved pharmacokinetic profiles exemplified by the data in Figures 4B and 4C.

权利要求:
Claims (7)
[0001]
1. Fusion protein, characterized by the fact that it comprises a variant of FGF21 and an Fc region, in which the variant of FGF21 comprises the following mutations related to the hFGF21 full-length sequence SEQ ID NO: 1: Q55C, R105K , G148C, K150R, P158S, S195A, P199G and G202A.
[0002]
2. Fusion protein according to claim 1, characterized by the fact that it comprises the amino acid sequence of SEQ ID NO: 11.
[0003]
3. Fusion protein, according to claim 1, characterized by the fact that the FGF21 variant is fused to the said Fc region by a GS linker.
[0004]
4. Fusion protein according to claim 1, characterized by the fact that the Fc region is an Fc fragment modified with a LALA mutation.
[0005]
5. Fusion protein according to claim 1, characterized by the fact that it comprises at least one disulfide bond projected between Gln55Cys and a cysteine residue in one of Cys103, Cys121, Gly148Cys, Asn149Cys, Ser151Cys, Pro152Cys , His153Cys, Arg154Cys, Asp155Cys, Pro156Cys, Ala157Cys, Arg159Cys, Gly160Cys, Pro161Cus, Ala162Cys and Arg163Cys.
[0006]
6. Fusion protein according to claim 1, characterized by the fact that it comprises at least one disulfide bond projected between Gly148Cys and a cysteine residue in one of Cys103, Cys121, Arg47Cys, Tyr48Cys, Leu49Cys, Tyr50Cys, Thr51Cys, Asp52Cys , Asp53Cys, Ala54Cys, Gln55Cys, Gln56Cys, Thr57Cys, Glu58Cys, Gly160Cys, Pro161Cys, Ala162Cys, Arg163Cys and Phe164Cys.
[0007]
7. Fusion protein according to claim 6, characterized by the fact that it is further enhanced with the designed disulfide bond Gln55Cys-Gly148Cys.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6567613B2|2019-08-28|Fusion proteins for treating metabolic disorders

---

JP2017110010A|2017-06-22|Methods for treating fgf21-associated disorders

---

JP6152380B2|2017-06-21|Dual functional protein for treating metabolic disorders

---

AU2015202304C1|2017-03-09|Fusion proteins for treating metabolic disorders

---

AU2016202834A1|2016-05-19|Fusion proteins for treating metabolic disorders

---

Boettcher et al.2013|Patent: Fusion Proteins for Treating Metabolic Disorders

---

NZ622998B2|2016-11-01|Fusion proteins for treating metabolic disorders

同族专利:

---

公开号 | 公开日

---

ES2689762T3|2018-11-15|

---

LT2760475T|2018-10-25|

---

CA2849464A1|2013-04-04|

---

US20160193297A1|2016-07-07|

---

CU24206B1|2016-10-28|

---

IL231533D0|2014-04-30|

---

CU20150171A7|2016-07-29|

---

US9266935B2|2016-02-23|

---

MX350273B|2017-08-31|

---

EP2760475A1|2014-08-06|

---

US10076554B2|2018-09-18|

---

DK2760475T3|2018-10-15|

---

SG11201400538QA|2014-06-27|

---

IL231533A|2018-06-28|

---

KR102085605B1|2020-03-06|

---

TN2014000109A1|2015-07-01|

---

TWI593708B|2017-08-01|

---

CN107266579A|2017-10-20|

---

EP3321276B1|2021-07-28|

---

JP6186361B2|2017-08-23|

---

US11129874B2|2021-09-28|

---

PL3321276T3|2022-01-17|

---

PL2760475T3|2018-11-30|

---

CL2014000736A1|2014-10-03|

---

PT3321276T|2021-10-27|

---

NZ622998A|2016-07-29|

---

DK3321276T3|2021-10-25|

---

EA201490695A1|2015-10-30|

---

TW201326213A|2013-07-01|

---

LT3321276T|2021-11-10|

---

CL2016002215A1|2016-10-28|

---

KR20140069250A|2014-06-09|

---

SI2760475T1|2018-10-30|

---

ES2895080T3|2022-02-17|

---

SI3321276T1|2021-11-30|

---

CR20140140A|2014-07-15|

---

JP2014534172A|2014-12-18|

---

SG10201602339XA|2016-05-30|

---

MX2014003677A|2014-04-30|

---

EP3321276A3|2018-06-20|

---

UY34346A|2013-04-30|

---

US20130079500A1|2013-03-28|

---

US20180369332A1|2018-12-27|

---

CN103945871B|2017-04-26|

---

PE20181159A1|2018-07-19|

---

CU20140034A7|2014-08-28|

---

AR088044A1|2014-05-07|

---

AU2012316052A1|2014-04-17|

---

RS62341B1|2021-10-29|

---

CU24314B1|2018-02-08|

---

MY166059A|2018-05-22|

---

US20150166622A1|2015-06-18|

---

CY1120928T1|2019-12-11|

---

JP2018023370A|2018-02-15|

---

JO3476B1|2020-07-05|

---

PT2760475T|2018-10-25|

---

CN103945871A|2014-07-23|

---

HUE055584T2|2021-12-28|

---

PE20141551A1|2014-10-26|

---

AP2014007543A0|2014-03-31|

---

BR112014007069A2|2017-03-28|

---

UA113856C2|2017-03-27|

---

RS57868B1|2018-12-31|

---

CO6920257A2|2014-04-10|

---

US20210386824A1|2021-12-16|

---

ZA201401700B|2015-01-28|

---

HRP20181558T1|2018-11-30|

---

IN2014DN02043A|2015-05-15|

---

JP6567613B2|2019-08-28|

---

GT201400055A|2017-09-28|

---

EP3321276A2|2018-05-16|

---

MA35437B1|2014-09-01|

---

HRP20211575T1|2022-02-04|

---

UY39119A|2021-04-30|

---

HK1251238A1|2019-01-25|

---

JP2020007314A|2020-01-16|

---

HUE039857T2|2019-02-28|

---

WO2013049247A1|2013-04-04|

---

EP2760475B1|2018-07-04|

---

US9006400B2|2015-04-14|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3773919A|1969-10-23|1973-11-20|Du Pont|Polylactide-drug mixtures|

---

US4263428A|1978-03-24|1981-04-21|The Regents Of The University Of California|Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same|

---

IE52535B1|1981-02-16|1987-12-09|Ici Plc|Continuous release pharmaceutical compositions|

---

EP0088046B1|1982-02-17|1987-12-09|Ciba-Geigy Ag|Lipids in the aqueous phase|

---

HUT35524A|1983-08-02|1985-07-29|Hoechst Ag|Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance|

---

EP0143949B1|1983-11-01|1988-10-12|TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION|Pharmaceutical composition containing urokinase|

---

EP0315456B1|1987-11-05|1994-06-01|Hybritech Incorporated|Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics|

---

US6565841B1|1991-03-15|2003-05-20|Amgen, Inc.|Pulmonary administration of granulocyte colony stimulating factor|

---

WO1993015722A1|1992-02-07|1993-08-19|Syntex Inc.|Controlled delivery of pharmaceuticals from preformed porous microparticles|

---

US5234784A|1992-04-01|1993-08-10|Eastman Kodak Company|Method of making a projection viewable transparency comprising an electrostatographic toner image|

---

US5824784A|1994-10-12|1998-10-20|Amgen Inc.|N-terminally chemically modified protein compositions and methods|

---

US6096871A|1995-04-14|2000-08-01|Genentech, Inc.|Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life|

---

CA2249195A1|1996-03-18|1997-09-25|Board Of Regents, The University Of Texas System|Immunoglobin-like domains with increased half lives|

---

US6660843B1|1998-10-23|2003-12-09|Amgen Inc.|Modified peptides as therapeutic agents|

---

US7459540B1|1999-09-07|2008-12-02|Amgen Inc.|Fibroblast growth factor-like polypeptides|

---

US6716626B1|1999-11-18|2004-04-06|Chiron Corporation|Human FGF-21 nucleic acids|

---

AT446365T|1999-11-18|2009-11-15|Novartis Vaccines & Diagnostic|HUMAN FGF-21 GEN AND GENE EXPRESSION PRODUCTS|

---

DE60043957D1|1999-12-23|2010-04-15|Zymogenetics Inc|Method of treating inflammation|

---

AU2002322394A1|2001-07-30|2003-02-17|Eli Lilly And Company|Method for treating diabetes and obesity|

---

CA2545539A1|2003-10-15|2005-04-28|Pdl Biopharma, Inc.|Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig|

---

BRPI0416683A|2003-12-10|2007-01-30|Lilly Co Eli|human 21 fibroblast growth factor mutant , or a biologically active peptide thereof, polynucleotide, expression vector, host cell, process for producing a polypeptide, pharmaceutical composition, method for treating a patient, and, use da muteìna fgf-21|

---

US7576190B2|2004-05-13|2009-08-18|Eli Lilly And Company|FGF-21 fusion proteins|

---

CA2575753A1|2004-09-02|2006-03-16|Eli Lilly And Company|Muteins of fibroblast growth factor 21|

---

EP1846019A2|2005-01-21|2007-10-24|Eli Lilly And Company|Method for treating cardiovascular disease|

---

JOP20190083A1|2008-06-04|2017-06-16|Amgen Inc|Fgf21 mutant fusion polypeptides and uses thereof|

---

WO2010048582A1|2008-10-24|2010-04-29|Irm Llc|Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues|

---

CA2760196C|2009-05-05|2019-02-26|Amgen Inc.|Fgf21 mutants and uses thereof|

---

CA2760674A1|2009-05-05|2010-11-11|Amgen Inc.|Fgf21 mutants and uses thereof|

---

AU2010262927A1|2009-06-17|2012-01-19|Amgen Inc.|Chimeric FGF19 polypeptides and uses thereof|

---

TW201130511A|2009-12-22|2011-09-16|Novartis Ag|Soluble proteins for use as therapeutics|

---

DE102010038140B4|2010-10-13|2020-06-18|Hettich-Heinze Gmbh & Co. Kg|Fitting for a sliding door|

---

US9023791B2|2010-11-19|2015-05-05|Novartis Ag|Fibroblast growth factor 21 mutations|

---

JO3476B1|2011-09-26|2020-07-05|Novartis Ag|Fusion proteins for treating metabolic disorders|

---

US9458214B2|2011-09-26|2016-10-04|Novartis Ag|Dual function fibroblast growth factor 21 proteins|

---

WO2015138278A1|2014-03-11|2015-09-17|Novartis Ag|Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling|EP2041167B1|2006-07-25|2010-05-12|Lipoxen Technologies Limited|Derivatisation of granulocyte colony-stimulating factor|

---

JP2010523084A|2007-03-30|2010-07-15|アンブルックス，インコーポレイテッド|Modified FGF-21 polypeptide|

---

US8822663B2|2010-08-06|2014-09-02|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

---

EP2625189B1|2010-10-01|2018-06-27|ModernaTX, Inc.|Engineered nucleic acids and methods of use thereof|

---

WO2012135805A2|2011-03-31|2012-10-04|modeRNA Therapeutics|Delivery and formulation of engineered nucleic acids|

---

MX349869B|2011-07-01|2017-08-17|Ngm Biopharmaceuticals Inc|Compositions, uses and methods for treatment of metabolic disorders and diseases.|

---

US9464124B2|2011-09-12|2016-10-11|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

---

JO3476B1|2011-09-26|2020-07-05|Novartis Ag|Fusion proteins for treating metabolic disorders|

---

US9458214B2|2011-09-26|2016-10-04|Novartis Ag|Dual function fibroblast growth factor 21 proteins|

---

CN110511939A|2011-10-03|2019-11-29|现代泰克斯公司|Nucleosides, nucleotide and nucleic acid of modification and application thereof|

---

AU2012352180A1|2011-12-16|2014-07-31|Moderna Therapeutics, Inc.|Modified nucleoside, nucleotide, and nucleic acid compositions|

---

US9283287B2|2012-04-02|2016-03-15|Moderna Therapeutics, Inc.|Modified polynucleotides for the production of nuclear proteins|

---

US9572897B2|2012-04-02|2017-02-21|Modernatx, Inc.|Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins|

---

US9878056B2|2012-04-02|2018-01-30|Modernatx, Inc.|Modified polynucleotides for the production of cosmetic proteins and peptides|

---

AU2013243955B2|2012-04-02|2018-02-22|Modernatx, Inc.|Modified polynucleotides for the production of oncology-related proteins and peptides|

---

EP2922554B1|2012-11-26|2022-02-23|ModernaTX, Inc.|Terminally modified rna|

---

EP2925775B1|2012-11-28|2020-09-16|NGM Biopharmaceuticals, Inc.|Compositions and methods for treatment of metabolic disorders and diseases|

---

US9290557B2|2012-11-28|2016-03-22|Ngm Biopharmaceuticals, Inc.|Compositions comprising variants and fusions of FGF19 polypeptides|

---

KR20150104579A|2012-12-27|2015-09-15|엔지엠 바이오파마슈티컬스, 아이엔씨.|Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases|

---

US9273107B2|2012-12-27|2016-03-01|Ngm Biopharmaceuticals, Inc.|Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases|

---

US8980864B2|2013-03-15|2015-03-17|Moderna Therapeutics, Inc.|Compositions and methods of altering cholesterol levels|

---

WO2015048744A2|2013-09-30|2015-04-02|Moderna Therapeutics, Inc.|Polynucleotides encoding immune modulating polypeptides|

---

US10323076B2|2013-10-03|2019-06-18|Modernatx, Inc.|Polynucleotides encoding low density lipoprotein receptor|

---

WO2015057908A1|2013-10-18|2015-04-23|Novartis Ag|Methods of treating diabetes and related disorders|

---

CN113769114A|2013-10-28|2021-12-10|恩格姆生物制药公司|Cancer models and related methods|

---

CN106662577B|2014-01-24|2020-07-21|恩格姆生物制药公司|Binding proteins and methods of use thereof|

---

WO2015138278A1|2014-03-11|2015-09-17|Novartis Ag|Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling|

---

US10398758B2|2014-05-28|2019-09-03|Ngm Biopharmaceuticals, Inc.|Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions|

---

CA2951153A1|2014-06-16|2015-12-23|Ngm Biopharmaceuticals, Inc.|Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases|

---

BR112017007816A2|2014-10-23|2017-12-19|Ngm Biopharmaceuticals Inc|pharmaceutical compositions comprising peptide variants and methods of using them|

---

KR20170070227A|2014-10-24|2017-06-21|브리스톨-마이어스 스큅 컴퍼니|Modified fgf-21 polypeptides and uses thereof|

---

WO2016073855A1|2014-11-07|2016-05-12|Ngm Biopharmaceuticals, Inc.|Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders|

---

KR20160088656A|2015-01-16|2016-07-26|주식회사유한양행|Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same|

---

WO2017019957A2|2015-07-29|2017-02-02|Ngm Biopharmaceuticals, Inc.|Binding proteins and methods of use thereof|

---

EP3331914A1|2015-08-03|2018-06-13|Novartis AG|Methods of treating fgf21-associated disorders|

---

ES2871036T3|2015-11-09|2021-10-28|Ngm Biopharmaceuticals Inc|Method for treating bile acid-related disorders|

---

TW201731867A|2015-12-02|2017-09-16|賽諾菲公司|FGF21 variants|

---

MX2018014256A|2016-05-20|2019-08-16|Harvard College|Gene therapy methods for age-related diseases and conditions.|

---

CA3026510A1|2016-05-25|2017-11-30|Board Of Regents, The University Of Texas System|Methods and compositions for the treatment of secretory disorders|

---

CN107759696A|2016-08-19|2018-03-06|安源医药科技（上海）有限公司|Fusion protein of human interleukin 7 and preparation method thereof|

---

WO2018032638A1|2016-08-19|2018-02-22|安源医药科技（上海）有限公司|Linker peptide for constructing fusion protein|

---

CN110087671A|2016-12-22|2019-08-02|赛诺菲|FGF21 compound/GLP-1R agonist combinations of activity ratio with optimization|

---

JP2020509761A|2017-03-14|2020-04-02|サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ．|Dual target fusion protein containing Fc portion of immunoglobulin|

---

CN107050429B|2017-04-01|2020-12-15|杭州生物医药创新研究中心|Application of human fibroblast growth factor 21 in preparing medicine for treating cerebral apoplexy|

---

CN109836504A|2017-11-24|2019-06-04|浙江道尔生物科技有限公司|A kind of Multidomain activated protein for treating metabolic disease|

---

CN111601613A|2017-12-22|2020-08-28|诺华股份有限公司|Methods of treating metabolic disorders with FGF21 variants|

---

SG11202013240RA|2018-07-03|2021-01-28|Squibb Bristol Myers Co|Fgf21 formulations|

---

EP3736574A1|2019-05-07|2020-11-11|Atlas Antibodies AB|A formulation comprising an isotope labeled fusion polypeptide|

---

CN111944055A|2019-05-16|2020-11-17|浙江道尔生物科技有限公司|Fusion protein for treating metabolic diseases|

---

US11058725B2|2019-09-10|2021-07-13|Obsidian Therapeutics, Inc.|CA2 compositions and methods for tunable regulation|

---

TW202135811A|2019-12-20|2021-10-01|瑞士商諾華公司|Combination treatment of liver diseases using integrin inhibitors|

---

CN113265007B|2021-06-10|2022-02-15|江南大学|Fusion protein for treating metabolic diseases and preparation method and application thereof|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-03-27| B15K| Others concerning applications: alteration of classification|Ipc: A61K 38/18 (2006.01), A61K 45/06 (2006.01), C07K 1 |

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-07-31| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2019-08-06| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-09-01| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-12-15| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161539280P| true| 2011-09-26|2011-09-26|

---

US61/539,280|2011-09-26|

---

PCT/US2012/057384|WO2013049247A1|2011-09-26|2012-09-26|Fusion proteins for treating metabolic disorders|

---